USRE37979E1 - Pyrimidine derivatives and anti-viral agent containing the same as active ingredient thereof - Google Patents

Pyrimidine derivatives and anti-viral agent containing the same as active ingredient thereof Download PDF

Info

Publication number
USRE37979E1
USRE37979E1 US08/957,358 US95735897A USRE37979E US RE37979 E1 USRE37979 E1 US RE37979E1 US 95735897 A US95735897 A US 95735897A US RE37979 E USRE37979 E US RE37979E
Authority
US
United States
Prior art keywords
group
alkyl
optionally substituted
halogen atom
substituents selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US08/957,358
Inventor
Tadashi Miyasaka
Hiromichi Tanaka
Erik Desiré DeClercq
Masanori Baba
Richard Thomas Walker
Masaru Ubasawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsubishi Chemical Corp
Original Assignee
Mitsubishi Chemical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP20059590A external-priority patent/JPH0483881A/en
Priority claimed from US08/222,071 external-priority patent/US5461060A/en
Application filed by Mitsubishi Chemical Corp filed Critical Mitsubishi Chemical Corp
Priority to US08/957,358 priority Critical patent/USRE37979E1/en
Assigned to MITSUBISHI CHEMICAL CORPORATION reassignment MITSUBISHI CHEMICAL CORPORATION CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: MITSUBISHI KASEI CORPORATION
Application granted granted Critical
Publication of USRE37979E1 publication Critical patent/USRE37979E1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56—One oxygen atom and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/58—Two sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms

Definitions

  • the present invention relates to novel 6-substituted acyclopyrimidine derivatives and antiviral agents containing the derivative as the active ingredients.
  • HIV human acquired immunodeficiency virus
  • a compound of 3′-deoxy-3′-azidothymidine is known as a nucleoside compound used in the clinical treatment for diseases caused by HIV-infection.
  • this compound has side-effects since it also exhibits considerable strong toxicity in the host cells.
  • 6-substituted acyclopyrimidine nucleoside compounds such as 6-fluoro substituted derivatives, 6-alkylamino substituted derivatives (DD-A-232492) and 6-methyl substituted derivatives (C. A. 107, 129717w (1987)) are known; however, the antiviral activity of these compounds has not been described.
  • the present invention concerns 6-substituted acyclopyrimidine nucleoside derivatives represented by the following general formula I;
  • R 1 represents a hydrogen atom, halogen atom, alkyl, cycloalkyl, alkenyl, alkynyl, alkylcarbonyl, arylcarbonyl, arylcarbonylalkyl, arylthio or aralkyl group;
  • R 2 represents an arylthio, alkylthio, cycloalkylthio, arylsulfinyl, alkylsulfinyl, cycloalkylsulfinyl, alkenyl, alkynyl, aralkyl, arylcarbonyl, arylcarbonylalkyl or aryloxy group, those groups optionally substituted by one or more of substituents selected from a halogen atom, alkyl, halogenated alkyl, alkoxy, hydroxyl, nitro, amino, cyano and acyl groups;
  • R 3 represents a hydrogen atom, methyl, branched alkyl or —CH 2 —Z—(CH 2 ) n —R 5 group
  • R 5 represents a hydrogen atom, halogen atom, hydroxyl, heterocyclic carbonyloxy, formyloxy, alkylcarbonyloxy, cycloalkylcarbonyloxy, aralkylcarbonyloxy, arylcarbonyloxy, azido, alkoxycarbonyloxy, N-alkylcarbamoyloxy, N-arylcarbamoyloxy, alkoxy, aralkyloxy, branched alkyl, cycloalkyl or aryl group, the alkoxycarbonyloxy to aryl groups mentioned above as R 5 optionally substituted by one or more substituents selected from a halogen atom, aryl, alkyl, alkoxy and halogenated alkyl groups
  • Z represents an oxygen, sulfur atom or methylene group
  • R 4 represents a hydrogen atom, alkyl or aralkyl group
  • X and Y represent an oxygen or sulfur atom independently, provided that when R 4 and Z represent a hydrogen atom and oxygen atom respectively R 5 does not represent a hydroxyl group, or the following general formula I′;
  • R 1 , R 2 , R 3 and Y have the same meanings as defined for the formula I above, pharmaceutically acceptable salts thereof and antiviral agents containing the derivative or the salt thereof as an active ingredient.
  • 6-substituted acyclopyrimidine nucleoside derivatives according to the invention are represented by the general formula I or I′.
  • R 1 represents a hydrogen atom; halogen atom such as chlorine, iodine, bromine and fluorine; alkyl group such as methyl, ethyl, n-propyl, i-propyl and n-butyl; cycloalkyl group such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl; alkenyl group such as vinyl, propenyl, butenyl, phenylvinyl, bromovinyl, cyanovinyl, alkoxycarbonylvinyl and carbamoylvinyl; alkynyl group such as ethynyl, propynyl and phenylethynyl; alkylcarbonyl group such as acetyl, propionyl, and i-butyryl; arylcarbonyl group such as benzoyl and naphthoyl
  • the group of R 2 represents an arylthio group such as phenylthio and naphthylthio; alkylthio group such as methylthio, ethylthio, propylthio, butylthio and pentylthio; cycloalkylthio group such as cyclopentylthio, cyclohexylthio and cycloheptylthio; arylsulfinyl group such as phenylsulfinyl; alkylsulfinyl group such as methylsulfinyl, ethylsulfinyl and butylsulfinyl; cycloalkylsulfinyl group such as cyclopentylsulfinyl and cyclohexylsulfinyl; alkenyl group such as vinyl, propenyl and phenylvinyl; alkynyl group such as ethyny
  • R 3 represents a hydrogen atom, methyl group, branched alkyl group such as i-propyl and t-butyl or —CH 2 —Z—(CH 2 ) n —R 5 group where R 5 represents a hydrogen atom; halogen atom such as fluorine, chlorine, iodine and bromine; hydroxyl group; heterocyclic carbonyloxy group such as nicotinoyloxy; formyloxy group; optionally branched alkylcarbonyloxy group such as acetoxy, propyonyloxy, n-butyryloxy, i-butyryloxy, valeryloxy, hexanoyloxy, heptanoyloxy and decanoyloxy; cycloalkylcarbonyloxy group such as cyclohexylcarbonyloxy; aralkylcarbonyloxy group such as benzylcarbonyloxy; arylcarbonyloxy group such as benzoyl
  • R 4 represents a hydrogen atom; optionally branched alkyl group such as methyl, ethyl, n-propyl, i-propyl, n-butyl and t-butyl; or aralkyl group such as benzyl.
  • X and Y represent oxygen or sulfur atom independently.
  • R 4 and Z represent a hydrogen atom and oxygen atom respectively, R 5 does not represent a hydroxyl group.
  • the preferred compounds according to the invention have R 1 of a hydrogen atom, halogen atom, C 1 to C 5 alkyl group or C 2 to C 5 alkenyl group, particularly C 1 to C 5 alkyl group; R 2 of C 6 to C 10 arylthio group, C 3 to C 10 cycloalkylthio group or C 7 to C 11 aralkyl group, particularly C 6 to C 10 arylthio, C 3 to C 10 cycloalkylthio or C 7 to C 11 aralkyl group, optionally substituted by one or more substituents selected from a halogen atom, C 1 to C 5 alkyl, C 1 to C 5 alkoxy and nitro groups; R 3 of a hydrogen atom, methyl or —CH 2 —Z—(CH 2 ) n —R 5 group where R 5 represents a hydrogen atom, halogen atom, hydroxyl, heterocyclic carbonyloxy, C 2 to C 11 alkylcarbonyloxy, C 4 to
  • R 3 represents methyl or branched alkyl or —CH2—Z(CH 2 ) n —R 5 group where R 5 represents a hydrogen, halogen atom, azido, alkoxy, aralkyloxy, optionally substituted aryl group or the like may be prepared in accordance with the following reaction formula (1), (2) or (3):
  • R 1 , R 2 , R 3 , R 4 , X and Y have the same meanings defined hereinbefore, X 1 and X 2 represent a halogen atom, arylthio, alkoxy group or the like, and M represents an alkaline metal.
  • the compound of the formula II or IV is treated with an organic alkali metal compound in an ether solvent such as diethyl ether and tetrahydrofuran at a temperature of ⁇ 80° to ⁇ 10° C. for 0.2 to 10 hours.
  • an ether solvent such as diethyl ether and tetrahydrofuran
  • lithium alkylamides are preferably prepared immediately before the reaction.
  • lithium dialkylamide may be prepared by reacting a secondary amine such as diisopropylamine with an alkyl lithium such as n-butyl lithium in a solvent such as diethyl ether, dioxane, tetrahydrofuran and dimethoxyethane with stirring under the atmosphere of an inert gas such as argon at ⁇ 80° C. to ⁇ 10° C. for 0.2 to 5 hours.
  • the organic alkali metal compound is usually used in an amount of 1 to 5 moles per mole of the compound of the general formula II or IV.
  • the electrophilic reagent of the general formula R 2 X 1 or R 1 X 2 is added to the reaction mixture in a ratio of about 1 to 5 moles to the compound of the general formula II or IV to allow the reaction under the same condition as in the reaction with the organic alkali metal compound.
  • the electrophilic reagent should have a group of R 1 or R 2 defined above, and examples of this reagent includes various diaryl disulfides, arylsulfenyl chlorides, dialkyl disulfides, dicycloalkyl disulfides, alkyl halides, aralkyl halides such as benzyl bromide, acid halides such as benzoyl halide and isobutyric halide, acid anhydrides and esters thereof, aryl-carbonylalkyl halides such as phenacyl chloride and the like.
  • the compounds of the general formula II can be prepared by a conventional method.
  • the compounds of the general formula IV can be prepared in accordance with the reaction formula (I) above (R 1 ⁇ H).
  • R 1 , R 2 , R 3 , R 4 , X and Y have the same meanings defined hereinbefore and X 3 represents a halogen atom such as chlorine, bromine and iodine or sulfonyloxy group such as toluenesulfonyloxy and mesyloxy groups.
  • the compounds of the general formula VI are treated with an acid such as hydrochloric acid and bromic acid in a suitable solvent, for example, an alcohol such as methanol and ethanol and water at an appropriate temperature of from room temperature to 100° C. to obtain the compounds of the general formula VII.
  • a suitable solvent for example, an alcohol such as methanol and ethanol and water at an appropriate temperature of from room temperature to 100° C.
  • the compounds of the general formula VII are reacted with the compounds of the general formula VIII in a suitable solvent such as dimethylformamide, dimethyl sulfoxide, acetonitrile and tetrahydrofuran in the presence of a suitable base such as sodium hydride, sodium alkoxide, potassium alkoxide, potassium carbonate and sodium carbonate at a temperature of from ambient temperature to the boiling point of the solvent to obtain the compounds of the general formula I.
  • a suitable solvent such as dimethylformamide, dimethyl sulfoxide, acetonitrile and tetrahydrofuran
  • a suitable base such as sodium hydride, sodium alkoxide, potassium alkoxide, potassium carbonate and sodium carbonate at a temperature of from ambient temperature to the boiling point of the solvent to obtain the compounds of the general formula I.
  • the starting compounds represented by the general formula VI can be prepared in accordance with the reaction formula (1) or (2).
  • the reactions of (1) and (2) should be carried out using a starting compound or intermediate compound of which hydroxyl group is protected by an appropriate protective group instead of the unprotected compound of the formula II or IV or the like, and the protective group is then eliminated to obtain the target compound.
  • Any protective groups conventionally used for the protection of hydroxyl group may be used for this purpose so long as it is not eliminated under the alkaline condition.
  • Examples of such protective group are aralkyl groups such as benzyl, trityl, monomethoxytrityl, dimethoxytrityl and trimethoxytrityl, silyl groups such as trimethylsilyl, triethylsilyl, t-butyldimethylsilyl and t-butyldiphenylsilyl, tetrahydropyranyl group and substituted alkyl groups such as methoxymethyl group.
  • silyl groups are particularly preferred.
  • the introduction of the protective group can be carried out by a conventional method.
  • the introduction of the protective silyl group may be carried out by reacting the compound having the hydroxyl group with 1 to 10 times by mole of silylating reagent such as trimethylsilyl chloride and t-butyldimethylsilyl chloride at a temperature of from 0° to 50° C. in the presence of a base such as pyridine, picoline, diethylaniline, dimethylaniline, triethylamine and imidazole in a solvent such as dimethylformamide, acetonitrile, tetrahydrofuran and a mixture of those solvents in any combination.
  • silylating reagent such as trimethylsilyl chloride and t-butyldimethylsilyl chloride at a temperature of from 0° to 50° C.
  • a base such as pyridine, picoline, diethylaniline, dimethylaniline, triethylamine and imidazole
  • a solvent such as dimethylformamide,
  • the elimination of the protective group may be carried out by a conventional method corresponding to the kind of the protective group, for example, acid hydrolysis, ammonium fluoride treatment or catalytic reduction.
  • the compounds obtained by the reactions (1), (2) or (3) which have a nitro substituted phenylthio group at the 6-position may be converted into the compounds having an amino group by hydrogenation in accordance with the reaction formula (4) below.
  • the hydrogenation can be carried out in an organic solvent such as alcohol and acetic acid in the presence of a catalyst such as palladium/carbon at an appropriate temperature of from room temperature to 80° C.:
  • the compounds having an arylthio, alkylthio or cycloalkylthio group can be converted to corresponding compounds having an arylsulfinyl, alkylsulfinyl or cycloalkylsulfinyl group by using an oxidizing agent such as hydrogen peroxide and m-chloroperbenzoic acid in accordance with the reaction formula (5) below:
  • R 6 represents an aryl, alkyl or cycloalkyl group and the other symbols have the same meanings as defined above.
  • the compounds having phenyl sulfoxide group can be converted into corresponding compounds having a substituted arylthio or aryloxy group by reacting with sodium arylthiolate or sodium aryloxide having various substituents on the benzene ring in an organic solvent such as tetrahydrofuran, alcohol, dimethylformamide and acetonitrile at an appropriate temperature of from room temperature to 100° C. in accordance with the reaction formula (6) below:
  • R 7 and R 8 independently represent a halogen atom such as chlorine, bromine, fluorine and iodine, alkyl group such as methyl, ethyl, propyl and butyl, halogenated alkyl group such as trichloromethyl, alkoxy group such as methoxy, ethoxy, propoxy and butoxy, hydroxyl group, nitro group, amino group, cyano group and acyl group such as acetyl, and the other symbols have the same meanings as defined above.
  • halogen atom such as chlorine, bromine, fluorine and iodine
  • alkyl group such as methyl, ethyl, propyl and butyl
  • halogenated alkyl group such as trichloromethyl
  • alkoxy group such as methoxy, ethoxy, propoxy and butoxy
  • hydroxyl group nitro group
  • amino group cyano group and acyl group
  • acetyl and the other symbols
  • the present compounds may be also prepared in accordance with, for example, the reaction formula (7) or (8) below:
  • R 9 represents an alkyl group such as methyl and ethyl, aryl group such as phenyl and toluyl, a protective group such as silyl group or the like, and the other symbols have the same meanings as defined above.
  • the reactions of the formulae (7) and (8) can be carried out in an amine solvent such as diethylamine and triethylamine in the presence of a palladium catalyst at an appropriate temperature of from room temperature to 70° C.
  • the reactions may be carried but more homogeneously by adding another solvent such as acetonitrile.
  • a palladium catalyst of bis(triphenylphosphine)palladium dichloride, tetrakis(triphenylphosphine)palladium(O) and bis(diphenylphosphino)ethanepalladium dichloride can be used in combination with cuprous iodide.
  • the present compounds can be prepared also in accordance with the reaction formula (9) or (10) below, and the reactions may be carried out in the same manner as the reactions of the formulae (7) and (8) except that an olefin derivative of H 2 C ⁇ CH—R 10 wherein R 10 represents an alkoxycarbonyl, nitrile, carbamoyl group and the like is used instead of the acetylene derivative in the reactions of the formulae (7) and (8):
  • the palladium catalyst may be the same as in the reaction of the formulae (7) and (8).
  • X 4 represents a halogen atom such as chlorine, bromine and iodine, and the other symbols have the same meaning as defined above.
  • intermediate compounds are prepared in accordance with the reaction formulae (1) and (2) as described hereinbefore except that a compound of OCH-CH(R 11 )(R 12 ) wherein R 11 and R 12 independently represent a hydrogen atom, alkyl group such as methyl, ethyl and propyl or aryl group such as phenyl is used instead of the compounds R 1 X 2 and R 2 X 1 , and then the intermediate compounds are dehydrated by a dehydrating agent such as mesyl chloride, tosyl chloride and thionyl chloride to produce the compounds according to the invention having an alkenyl group.
  • a dehydrating agent such as mesyl chloride, tosyl chloride and thionyl chloride
  • the alkynyl group of the compounds produced in the reactions of the formula (7) or (8) can be converted into the corresponding alkenyl or alkyl group and the alkenyl group of the compound produced in any one of the reactions formulae (9) to (13) can be converted into the corresponding alkyl group.
  • the hydrogenation may be carried out at an appropriate temperature of from room temperature to 80° C. under hydrogen atmosphere in the presence of a catalyst such as palladium/barium sulfate, palladium/calcium carbonate, palladium/calcium carbonate/lead acetate and palladium/barium sulfate/quinoline in a solvent such as alcohol and acetic acid.
  • the hydrogenation may be carried out by using a catalyst such as palladium/carbon and palladium hydroxide under the same conditions as used for producing the alkenyl group.
  • 6-benzyl substituted derivatives of the invention may be prepared in accordance with the reaction formula (14) below:
  • intermediate compounds are prepared in the same way as the reactions of the formula (1) using OHC-R 13 where R 13 represents an optionally substituted aryl group such as phenyl instead of R 1 X 2 and the intermediate compounds are reduced by a suitable reducing agent to convert the hydroxyl group into a hydrogen atom.
  • the reduction can be carried out by using hydrogen gas in the presence of palladium/carbon or palladium hydroxide.
  • the 6-substituted acyclouridine or acyclothymidine derivatives obtained in the above-described reactions can be converted into 4-thio derivatives by heating them with 2,4-bis(4-methoxyphenyl)-1,3-dithia-2,4-diphosphetane-2,4-disulfide in a solvent such as toluene and xylene in accordance with the reaction formula (15) below:
  • the 4-thio derivatives can be also prepared by preparing corresponding 4-chloro derivatives by chlorination of corresponding uridine or thymidine derivatives by a chlorinating agent such as phosphorous pentachloride or phosphorous oxychloride and reacting the 4-chloro derivatives with sodium bisulfide.
  • a chlorinating agent such as phosphorous pentachloride or phosphorous oxychloride
  • 4-amino derivatives can be prepared by reacting the acyclouridine or thymidine derivatives with 1-(2-mesitylenesulfonyl)-3-nitro-1,2,4-triazole in the presence of diphenylphosphoric acid in a solvent such as pyridine to produce corresponding 4-(3-vitro-1,2,4-triazole) derivatives which are converted to the corresponding 4-amino derivatives by aqueous ammonia at an appropriate temperature of from room temperature to 100° C. in accordance with the reaction formula (16) below:
  • X5 represents a halogen atom such as chlorine, bromine and iodine or sulfonyloxy group such as toluenesulfonyloxy and mesyloxy, and the other symbols have the same meanings as defined hereinbefore.
  • the reaction of the formula (17) may be carried out in a suitable solvent such as tetrahydrofuran, acetonitrile, dimethylformamide, pyridine and alcohol in the presence of a base in an amount of 1 to 2 times of the starting compound at a suitable temperature from room temperature to the boiling point of the solvent.
  • a suitable solvent such as tetrahydrofuran, acetonitrile, dimethylformamide, pyridine and alcohol
  • a base in an amount of 1 to 2 times of the starting compound at a suitable temperature from room temperature to the boiling point of the solvent.
  • the base include sodium alkoxide, potassium alkoxide, potassium carbonate, sodium carbonate, sodium hydride and the like.
  • R14 represents an optionally branched alkyl group, optionally substituted aryl grow or heterocyclic group
  • X 6 represents a halogen atom such as chlorine, bromine and iodine or —OCOR 14 , and the other symbols have the same meanings as defined hereinbefore.
  • the reaction of the formula (18) may be carried out in a suitable solvent such as tetrahydrofuran, acetonitrile, dimethylformamide, pyridine, dichloromethane and chloroform in the presence of a base in an amount of 1 to 2 times of the starting compound at a suitable temperature from room temperature to the boiling point of the solvent.
  • a suitable solvent such as tetrahydrofuran, acetonitrile, dimethylformamide, pyridine, dichloromethane and chloroform
  • a base include triethylamine, pyridine, imidazole, sodium carbonate, potassium carbonate, sodium hydroxide and the like.
  • R 15 represents an optionally branched alkyl group or aralkyl group
  • X 7 represents a halogen atom such as chlorine, bromine and iodine or —OCOOR 15 , and the other symbols have the same meanings as defined hereinbefore.
  • the reaction of the formula (19) may be carried out in a suitable solvent such as tetrahydrofuran, acetonitrile, dimethylformamide, pyridine, dichloromethane and chloroform in the presence of a base in as amount of 1 to 2 times of the starting compound at a suitable temperature from room temperature to the boiling paint of the solvent.
  • a suitable solvent such as tetrahydrofuran, acetonitrile, dimethylformamide, pyridine, dichloromethane and chloroform
  • a base include triethylamine, pyridine, imidazole, sodium carbonate, potassium carbonate, sodium hydroxide and the
  • R 16 represents an optionally branched alkyl group or aralkyl group
  • X 8 represents a halogen atom such as chlorine, bromine and iodine or sulfonyloxy group such as toluenesulfonyloxy and mesyloxy, and the other symbols have the same meanings as defined hereinbefore.
  • the reaction of the formula (20) may be carried out in a suitable solvent such as tetrahydrofuran, acetonitrile, dimethylformamide, pyridine, dichloromethane and chloroform in the presence of a base in an amount of 1 to 2 times of the starting compound at a suitable temperature from room temperature to the boiling point of the solvent.
  • a suitable solvent such as tetrahydrofuran, acetonitrile, dimethylformamide, pyridine, dichloromethane and chloroform
  • a base include triethylamine, pyridine, imidazole, sodium carbonate, potassium carbonate, sodium hydroxide and the like.
  • R 17 represents an optionally branched alkyl group or aryl group
  • X 9 represents an oxygen or sulfur atom
  • the other symbols have the same meanings as defined hereinbefore.
  • the reaction of formula (21) may be carried out in an appropriate solvent such as tetrahydrofuran, acetonitrile, dimethylformamide, pyridine, dichloromethane and chloroform at an appropriate temperature of from room temperature to the boiling point of the solvent.
  • an appropriate solvent such as tetrahydrofuran, acetonitrile, dimethylformamide, pyridine, dichloromethane and chloroform
  • the compounds of the present invention obtained as described hereinbefore and represented by the formula I or I′ may be separated and purified by any of the conventional methods for the separation and purification of nucleosides, for example, recrystallization, adsorption chromatography, ion exchange chromatography and the like.
  • the compound of the invention represented by the formula I or I′ may be converted into a pharmaceutically acceptable salt thereof by a conventional method.
  • Such salt may be, for example, an alkali metal salt such as sodium or potassium salt, alkaline earth salt such as magnesium salt, ammonium salt or alkylammonium salt such as methylammonium, dimethylammonium, trimethylammonium, tetramethylammonium salt or the like.
  • the compounds according to invention can be administered to human beings via any route, oral, rectal, parenteral or local for the prevention or treatment of the infection of viruses such as retrovirus.
  • the administration dose of the compounds according to the invention may be determined according to age, physical condition, body weight and the like of a patient to be treated; however, a suitable daily does of the compounds is 1 to 100 mg/(body weight)kg, preferably 5 to 50 mg/(body weight)kg and it is administered in one to several times.
  • the compound of the invents is generally prepared in a pharmaceutical composition with a suitable carrier, excipient and other additives.
  • a suitable carrier either a liquid carrier or solid carrier may be suitably used for the present antiviral agent.
  • solid carrier examples include lactose, kaolin, sucrose, crystalline cellulose, corn starch, talc, agar, pectin, stearic acid, magnesium stearate, lecithin, sodium chloride and the like.
  • liquid examples include glycerin, peanut oil, polyvinyl pyrrolidone, olive oil, ethanol, benzyl alcohol, propylene glycol, water and the like.
  • the present antiviral agent may be made in various forms. For example, it may be in the form of a tablet, powder, granule, capsule; suppository, troche or the like when a solid carrier is used, and it may be also in the form of syrup, emulsion, soft gelatin capsule, cream, gel, paste, spray, injection solution, or the like when a liquid carrier is used.
  • novel 6-substituted ayclopyrimidine nucleoside derivatives according to the sent invention have an effective antiviral activity against viruses such as retrovirus and have a relatively low toxicity against the host cell, hence the derivatives of the invention are extremely useful as an active ingredient of antiviral agent.
  • Compound No. 14 was prepared in the same manner as Example 2 by using t-butoxycarbonyl chloride in place of acetic anhydride in Example 2.
  • Compound No. 15 was obtained in the same manner as Example 2 by using 1-[(2-hydroxyethoxy) methyl]-6-cyclohexylthiothymine and benzyloxycarbonyl chloride in place of 1-[(2-hydroxyethoxy)methyl]-6-phenylthiothymine and acetic anhydride in Example 2 respectively.
  • the reaction mixture was neutralized with acetic acid and distributed between chloroform and saturated aqueous solution of sodium by hydrogencarbonate, and the chloroform layer was concentrated to dryness under reduced pressure.
  • the residue was dissolved in a small amount of chloroform, adsorbed on a silica gel column and eluted with 1% methanol/chloroform.
  • the eluate was concentrated and crystallized from diethyl ether/hexane to obtain 0.64 g of the target compound (Yield: 80%).
  • the reaction mixture was added with 1 ml of acetic acid, brought to room temperature and then added with 30 ml of ethyl acetate.
  • the mixture was washed with water (3 mix 5) and saturated aqueous solution of sodium hydrogencarbonate (twice), dried on magnesium sulfate and′ concentrated under reduced pressure.
  • Compound No. 357 was obtained in the same way as Example 35 by using 3,3′,5,5′-tetramethylphenyl disulfide in place of diphenyl disulfide.
  • the reaction mixture was added with 1 ml of acetic acid, brought to room temperature and then added with 30 ml of ethyl acetate.
  • the mixture was washed with water (3 ml ⁇ 5) and saturated aqueous solution of sodium hydrogencarbonate (twice), dried on magnesium sulfate and concentrated under reduced pressure.
  • Compound No. 359 was prepared in the same way as Example 37 by using 3,3′,5,5′-tetramethyldiphenyl disulfide in place of diphenyl disulfide.
  • Compound No. 360 was prepared in the same way as Example 35 by using benzyl chloromethyl ether in place of chloromethyl ethyl ether.
  • Compound No. 361 was prepared in the same way as Example 35 by using benzyl chloromethyl ether and 3,3′,5,5′-tetramethyldiphenyl disulfide respectively in place of chloromethyl ethyl ether and diphenyl disulfide.
  • Compound No 362 was prepared in the same way as Example 35 by using thymine and benzyl chloromethyl ether in place of 5-ethyluracil and chloromethyl ethyl ether.
  • Compound No. 41 was prepared in the same way as Example 22 by using chloromethyl propyl ether in place of chloromethyl methyl ether.
  • Compound No. 485 was prepared in the same way as Example 22 by using butyl chloromethyl ether in place of chloromethyl methyl ether.
  • Compound No. 365 was prepared in the same way as Example 35 by using 3,3′,5,5′-tetrachlorodiphenyl disulfide in place of diphenyl disulfide.
  • Compound No. 366 was prepared in the same way as Example 35 by using 5-ethyl-2-thiouracil and 3,3′,5,5′-tetrachlorodiphenyl disulfide respectively in place of 5-ethyluracil and diphenyl disulfide.
  • Compound No. 496 was prepared in the same way as Example 35 by using 5-isopropyluracil in place of 5-ethyluracil.
  • Compound No. 497 was prepared in the same way as Example 35 by using 5-isopropyl-2-thiouracil in place of 5-ethyluracil.
  • Compound No. 574 was prepared in the same way as Example 35 by using 5-cyclopropyluracil in place of 5-ethyluracil.
  • Compound No. 575 was prepared in the same way as Example 35 by using 5-cyclopropyl-2-thiouracil in place of 5-ethyluracil.
  • Compound No. 675 was prepared in the same way as Example 35 by using chloromethyl isopropyl other in place of chloromethyl ethyl ether.
  • Compound No. 675 was prepared in the same way as Example 35 by using 5-ethyl-2-thiouracil and chloromethyl isopropyl ether respectively in place of 5-ethyluracil and chloromethyl ethyl ether.
  • Compound No. 685 was prepared in the same way as Example 35 by using chloromethyl cyclohexyl ether in place of chloromethyl ethyl ether.
  • Compound No. 689 was prepared in the same way as Example 35 by using chloromethyl cyclohexylmethyl ether in place of chloromethyl ethyl ether.
  • Compound No. 512 was prepared in the same way as Example 35 by using 5-isopropyluracil and benzyl chloromethyl ether respectively in place of 5-ethyluracil and chloromethyl ethyl ether.
  • Compound No. 513 was prepared in the same way as Example 35 by using 5-isopropyl-2-thiouracil and benzyl chloromethyl ether respectively in place of 5-ethyluracil and chloromethyl ethyl ether.
  • Compound No. 748 was prepared in the same way as Example 35 by using chloromethyl phenetyl ether in place of chloromethyl ethyl ether.
  • Compound No. 749 was prepared in the same way as Example 35 by using 5-ethyl-2-thioracil and chloromethyl phenetyl ether respectively in place of 5-ethyluracil and chloromethyl ethyl ether.
  • Compound No. 372 was prepared in the same way as Example 35 by using 5-ethyl-2-thiouracil and chloromethyl 4-methylbenzyl ether respectively in place of 5-ethyluracil and chloromethyl ethyl ether.
  • Compound No. 704 was prepared in the same way as Example 35 by using 5-ethyl-2-thiouracil and 4-chlorobenzyl chloromethyl ether respectively in place of 5-ethyluracil and chloromethyl ethyl ether.
  • reaction mixture was added with 1 ml of acetic acid, brought to room temperature and then added with 30 ml of ethyl acetate.
  • the mixture was washed with water (3 ml ⁇ 5) and saturated aqueous solution of sodium hydrogencarbonate (twice), dried on magnesium sulfate and concentrated under reduced pressure.
  • Compound No. 474 was prepared in the same way as Example 62 by using 3,5-dimethylbenzaldehyde in place of benzaldehyde.
  • Compound No. 363 was prepared in the same way as Example 35 by using 5-ethyl-2-thiouracil and benzyl chloromethyl ether respectively in place of 5-ethyluracil and chloromethyl ethyl ether.
  • Compound No. 364 was prepared in the same way as Example 35 by using 5-ethyl-2-thiouracil, benzyl chloromethyl ether and 3,3′,5,5′-tetramethyldiphenyl disulfide respectively in place of 5-ethyluracil, chloromethyl ethyl ether and diphenyl disulfide.
  • Each tablet had a weight of 100 mg and contained 10 mg of 1-](2-acetoxyethoxy)methyl]-6-phenylthiothymine 1 - [ ( 2 - acetoxyethoxy ) methyl] - 6 - phenylthiothymine.
  • RPMI 1640 DM culture medium containing 20 mM of Hepes buffer solution, 10% fetal bovine serum and 20 ⁇ g/ml of gentamycin, 3 ⁇ 10 4 MT-4 cells (human T cell clone which is destroyed by the infection of HIV) were infected with HIV in an amount of 100 times as large as expected to cause 50% infection of the cells.
  • MT-4 cells human T cell clone which is destroyed by the infection of HIV
  • MT-4 cells were cultured in the same way as above except that they were not infected with HIV to determine the concentration of the compound at which 50% of the MT-4 cells were destroyed.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The disclosure concerns pyrimidine derivatives represented by the following general formulas [I] and [I′] and having antiviral activity, particularly antiretroviral activity such as anti-HIV activity:
Figure USRE037979-20030204-C00001
and pharmaceutical compositions having antiviral activity and comprising the above-described derivative(s) as an active ingredient.

Description

This is a continuation of application Ser. No. 07/590,475 filed on Sep. 28, 1990, now abandoned.
FIELD OF THE INVENTION
The present invention relates to novel 6-substituted acyclopyrimidine derivatives and antiviral agents containing the derivative as the active ingredients.
BACKGROUND OF THE INVENTION
Infectious diseases caused by human acquired immunodeficiency virus (HIV), which is a type of retrovirus, have recently become a serious social problem. A compound of 3′-deoxy-3′-azidothymidine is known as a nucleoside compound used in the clinical treatment for diseases caused by HIV-infection. However, this compound has side-effects since it also exhibits considerable strong toxicity in the host cells.
Although some 2′,3′-dideoxyribonucleosides are known as nucleoside compounds exhibiting an anti-viral activity, it is still necessary to develop a substance possessing a higher activity and lower toxicity to the host cell (Hiroaki Mitsuya, Bodily Defense, Vol. 4, pp.213-223 (1987)).
On the other hand, various acyclonucleoside compounds have been synthesized since Acyclovir (acycloguanosine) was developed as an antiviral substance effective against herpes virus (C. K. Chu and S. J. Culter, J. Heterocyclic Chem., 23, p.289 (1986)). However, no acyclonucleoside compound having a sufficient activity especially against retroviruses has yet been discovered.
We have focussed our attention on 6-substituted acyclopyrimidine nucleoside compounds and have synthesized various novel 6-substituted acyclopyrimidine nucleoside derivatives and screened those compounds to detect effective antiviral agents, especially to the retrovirus, in order to provide antiviral agents exhibiting an effective activity particularly against retroviruses.
Some 6-substituted acyclopyrimidine nucleoside compounds such as 6-fluoro substituted derivatives, 6-alkylamino substituted derivatives (DD-A-232492) and 6-methyl substituted derivatives (C. A. 107, 129717w (1987)) are known; however, the antiviral activity of these compounds has not been described.
As a result of our researches for compounds exhibiting an effective antiviral activity, particularly anti-retroviral activity, we found that specific 6-substituted pyrimidine nucleoside compounds according to the invention satisfy the above demand to achieve the present invention.
SUMMARY OF THE INVENTION
The present invention concerns 6-substituted acyclopyrimidine nucleoside derivatives represented by the following general formula I;
Figure USRE037979-20030204-C00002
wherein R1 represents a hydrogen atom, halogen atom, alkyl, cycloalkyl, alkenyl, alkynyl, alkylcarbonyl, arylcarbonyl, arylcarbonylalkyl, arylthio or aralkyl group;
R2 represents an arylthio, alkylthio, cycloalkylthio, arylsulfinyl, alkylsulfinyl, cycloalkylsulfinyl, alkenyl, alkynyl, aralkyl, arylcarbonyl, arylcarbonylalkyl or aryloxy group, those groups optionally substituted by one or more of substituents selected from a halogen atom, alkyl, halogenated alkyl, alkoxy, hydroxyl, nitro, amino, cyano and acyl groups;
R3 represents a hydrogen atom, methyl, branched alkyl or —CH2—Z—(CH2)n—R5 group where R5 represents a hydrogen atom, halogen atom, hydroxyl, heterocyclic carbonyloxy, formyloxy, alkylcarbonyloxy, cycloalkylcarbonyloxy, aralkylcarbonyloxy, arylcarbonyloxy, azido, alkoxycarbonyloxy, N-alkylcarbamoyloxy, N-arylcarbamoyloxy, alkoxy, aralkyloxy, branched alkyl, cycloalkyl or aryl group, the alkoxycarbonyloxy to aryl groups mentioned above as R5 optionally substituted by one or more substituents selected from a halogen atom, aryl, alkyl, alkoxy and halogenated alkyl groups, Z represents an oxygen, sulfur atom or methylene group, and n represents 0 or an integer of 1 to 5,
R4 represents a hydrogen atom, alkyl or aralkyl group,
X and Y represent an oxygen or sulfur atom independently, provided that when R4 and Z represent a hydrogen atom and oxygen atom respectively R5 does not represent a hydroxyl group, or the following general formula I′;
Figure USRE037979-20030204-C00003
wherein R1, R2, R3 and Y have the same meanings as defined for the formula I above, pharmaceutically acceptable salts thereof and antiviral agents containing the derivative or the salt thereof as an active ingredient.
DETAILED DESCRIPTION OF THE INVENTION
The 6-substituted acyclopyrimidine nucleoside derivatives according to the invention are represented by the general formula I or I′.
The group of R1 represents a hydrogen atom; halogen atom such as chlorine, iodine, bromine and fluorine; alkyl group such as methyl, ethyl, n-propyl, i-propyl and n-butyl; cycloalkyl group such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl; alkenyl group such as vinyl, propenyl, butenyl, phenylvinyl, bromovinyl, cyanovinyl, alkoxycarbonylvinyl and carbamoylvinyl; alkynyl group such as ethynyl, propynyl and phenylethynyl; alkylcarbonyl group such as acetyl, propionyl, and i-butyryl; arylcarbonyl group such as benzoyl and naphthoyl; arylcarbonylalkyl group such as phenacyl; arylthio group such as phenylthio, tolylthio and naphthylthio; or aralkyl group such as benzyl.
The group of R2 represents an arylthio group such as phenylthio and naphthylthio; alkylthio group such as methylthio, ethylthio, propylthio, butylthio and pentylthio; cycloalkylthio group such as cyclopentylthio, cyclohexylthio and cycloheptylthio; arylsulfinyl group such as phenylsulfinyl; alkylsulfinyl group such as methylsulfinyl, ethylsulfinyl and butylsulfinyl; cycloalkylsulfinyl group such as cyclopentylsulfinyl and cyclohexylsulfinyl; alkenyl group such as vinyl, propenyl and phenylvinyl; alkynyl group such as ethynyl, propynyl and phenylethynyl; aralkyl group such as benzyl; arylcarbonyl group such as benzoyl; arylcarbonylalkyl group such as phenacyl; or aryloxy group such as phenoxy, and those groups may be optionally substituted by one or more of substituents selected from a halogen atom such as chlorine, bromine, fluorine and iodine, alkyl group such as methyl, ethyl, propyl, butyl and pentyl, a halogenated alkyl group such as trifluoromethyl, alkoxy group such as methoxy, ethoxy, propoxy and butoxy, hydroxyl group, nitro group, amino group, cyano group and acyl group such as acetyl.
The group of R3 represents a hydrogen atom, methyl group, branched alkyl group such as i-propyl and t-butyl or —CH2—Z—(CH2)n—R5 group where R5 represents a hydrogen atom; halogen atom such as fluorine, chlorine, iodine and bromine; hydroxyl group; heterocyclic carbonyloxy group such as nicotinoyloxy; formyloxy group; optionally branched alkylcarbonyloxy group such as acetoxy, propyonyloxy, n-butyryloxy, i-butyryloxy, valeryloxy, hexanoyloxy, heptanoyloxy and decanoyloxy; cycloalkylcarbonyloxy group such as cyclohexylcarbonyloxy; aralkylcarbonyloxy group such as benzylcarbonyloxy; arylcarbonyloxy group such as benzoyloxy, toluoylcarbonyloxy and naphthoylcarbonyloxy group; azido group; alkoxycarbonyloxy group such as methoxycarbonyloxy, ethoxycarbonyloxy, n-propoxycarbonyloxy, i-propoxycarbonyloxy, n-butoxycarbonyloxy and t-butoxycarbonyloxy group, optionally substituted by one or more substituents selected from a halogen atom such as fluorine, chlorine, bromine and iodine, aryl group such as phenyl, toluyl and naphthyl, alkyl group such as methyl, ethyl, n-propyl, i-propyl, n-butyl and t-butyl, alkoxy group such as methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy and t-butoxy and halogenated alkyl group such as trifluoromethyl; N-alkylcarbamoyloxy group such as N-methylcarbamoyloxy, N-ethylcarbamoyloxy, N-propylcarbamoyloxy, N-butylcarbamoyloxy and N-pentylcarbamoyloxy, optionally substituted by one or more substituents selected from a halogen atom such as fluorine, chlorine, bromine and iodine, aryl group such as phenyl, toluyl and naphthyl, alkyl group such as methyl, ethyl, n-propyl, i-propyl, n-butyl and t-butyl, alkoxy group such as methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy and t-butoxy and halogenated alkyl group such as trifluoromethyl; N-arylcarbamoyloxy group such as N-phenylcarbamoyloxy and N-tolylcarbamoyloxy, optionally substituted by one or more substituents selected from a halogen atom such as fluorine, chlorine, bromine and iodine, aryl group such as phenyl, toluyl and naphthyl, alkyl group such as methyl, ethyl, n-propyl, i-propyl, n-butyl and t-butyl, alkoxy group such as methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy and t-butoxy and halogenated alkyl group such as trifluoromethyl; N-alkylthiocarbamoyloxy group such as N-methytiocarbamoyloxy, N-ethylthiocarbamoyloxy, N-propylthiocarbamoyloxy, N-butylthiocarbamoyloxy and N-pentylthiocarbamoyloxy, optionally substituted by one or more substituents selected from a halogen atom such as fluorine, chlorine, bromine and iodine, aryl group such as phenyl, toluyl and naphthyl, alkyl group such as methyl, ethyl, n-propyl, i-propyl, n-butyl and t-butyl, alkoxy group such as methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy and t-butoxy and halogenated alkyl group such as trifluoromethyl; N-arylthiocarbamoyloxy group such as N-phenylthiocarbamoyloxy and N-tolylthiocarbamoyloxy, optionally substituted by one or more substituents selected from a halogen atom such as fluorine, chlorine, bromine and iodine, aryl group such as phenyl, toluyl and naphthyl, alkyl group such as methyl, ethyl, n-propyl, i-propyl, n-butyl and t-butyl, alkoxy group such as methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy and t-butoxy and halogenated alkyl group such as trifluoromethyl; alkoxy group such as methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, t-butoxy, n-pentyloxy and n-hexyloxy group, optionally substituted by one or more substituents selected from a halogen atom such as fluorine, chlorine, bromine and iodine, aryl group such as phenyl, toluyl and naphthyl, alkyl group such as methyl, ethyl, n-propyl, i-propyl, n-butyl and t-butyl, alkoxy group such as methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy and t-butoxy and halogenated alkyl group such as trifluoromethyl; branched alkyl group such as i-propyl, i-butyl, sec-butyl, t-butyl, i-heptyl and i-hexyl, optionally substituted by one or more substituents selected from a halogen atom such as fluorine, chlorine, bromine and iodine, aryl group such as phenyl, toluyl and naphthyl, alkyl group such as methyl, ethyl, n-propyl, i-propyl, n-butyl and t-butyl, alkoxy group such as methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy and t-butoxy and halogenated alkyl group such as trifluoromethyl; cycloalkyl group such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl, optionally substituted by one or more substituents selected from a halogen atom such as fluorine, chlorine, bromine and iodine, aryl group such as phenyl, toluyl and naphthyl, alkyl group such as methyl, ethyl, n-propyl, i-propyl, n-butyl and t-butyl, alkoxy group such as methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy and t-butoxy and halogenated alkyl group such as trifluoromethyl; or aryl group such as phenyl, optionally substituted by one or more substituents selected from a halogen atom such as fluorine, chlorine, bromine and iodine, aryl group such as phenyl, toluyl and naphthyl, alkyl group such as methyl, ethyl, n-propyl, i-propyl, n-butyl and t-butyl, an alkoxy group such as methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy and t-butoxy and halogenated alkyl group such as trifluoromethyl, and Z represents an oxygen, sulfur atom or methylene group, and n represents 0 or an integer of 1 to 5,
R4 represents a hydrogen atom; optionally branched alkyl group such as methyl, ethyl, n-propyl, i-propyl, n-butyl and t-butyl; or aralkyl group such as benzyl.
X and Y represent oxygen or sulfur atom independently.
In the above formula I, when R4 and Z represent a hydrogen atom and oxygen atom respectively, R5 does not represent a hydroxyl group.
The preferred compounds according to the invention have R1 of a hydrogen atom, halogen atom, C1 to C5 alkyl group or C2 to C5 alkenyl group, particularly C1 to C5 alkyl group; R2 of C6 to C10 arylthio group, C3 to C10 cycloalkylthio group or C7 to C11 aralkyl group, particularly C6 to C10 arylthio, C3 to C10 cycloalkylthio or C7 to C11 aralkyl group, optionally substituted by one or more substituents selected from a halogen atom, C1 to C5 alkyl, C1 to C5 alkoxy and nitro groups; R3 of a hydrogen atom, methyl or —CH2—Z—(CH2)n—R5 group where R5 represents a hydrogen atom, halogen atom, hydroxyl, heterocyclic carbonyloxy, C2 to C11 alkylcarbonyloxy, C4 to C10 cycloalkylcarbonyloxy, C8 to C12 aralkylcarbonyloxy, C7 to C13 arylcarbonyloxy, C2 to C11 alkoxycarbonyloxy, C8 to C10 aralkyloxycarbonyloxy, C2 to C8 N-alkylcarbamoyloxy, C7 to C13 arylcarbamoyloxy, C2 to C8 alkylthiocarbamoyloxy, C7 to C13 arylthiocarbamoyloxy, C1 to C10 alkoxy, C7 to C13 aralkyloxy, azido, C3 to C5 branched alkyl, C5 to C7 cycloalkyl or C6 to C10 aryl group optionally substituted by one or more substituents selected from a halogen atom, aryl, alkyl, alkoxy and halogenated alkyl groups, Z represents an oxygen, sulfur atom or methylene group, and n represents 0 or an integer of 1 to 5; R4 of a hydrogen atom, C1 to C13 alkyl or C7 to C11 aralkyl group; X of an oxygen or sulfur atom; and Y of an oxygen or sulfur atom; provided that when R4 and Z represent a hydrogen atom and oxygen atom respectively R5 does not represent hydroxyl group,
Examples of the preferred compounds according to the present invention are listed in Table 1 below. t,120
TABLE 1
Figure USRE037979-20030204-C00004
Com- Melting
pound point
No. R1 R2 R3 R4 X Y (° C.)
 1 —CH3
Figure USRE037979-20030204-C00005
Figure USRE037979-20030204-C00006
 		—H O S 112˜ 113
 2 ″ ″ ″ ″ ″ O 112˜ 113
 3 ″
Figure USRE037979-20030204-C00007
 		″ ″ ″ ″ 155.5˜ 156.6
 4 ″ ″ ″ ″ ″ S 144˜ 145
 5 ″
Figure USRE037979-20030204-C00008
 		″ ″ ″ O 132˜ 133
 6 ″
Figure USRE037979-20030204-C00009
 		″ ″ ″ ″ 100˜ 115
 7 ″
Figure USRE037979-20030204-C00010
Figure USRE037979-20030204-C00011
 		″ ″ ″ 120˜ 121
 8 ″ ″
Figure USRE037979-20030204-C00012
 		″ ″ ″ 107˜ 108
 9 ″ ″
Figure USRE037979-20030204-C00013
 		″ ″ ″ 9˜102
 10 —CH3
Figure USRE037979-20030204-C00014
Figure USRE037979-20030204-C00015
 		—H O O 80˜81
 11 ″ ″
Figure USRE037979-20030204-C00016
 		″ ″ ″ 101˜ 102
 12 ″ ″
Figure USRE037979-20030204-C00017
 		″ ″ ″ 132˜ 133
 13 ″ ″
Figure USRE037979-20030204-C00018
 		″ ″ ″ 139˜ 140
 14 ″ ″
Figure USRE037979-20030204-C00019
 		″ ″ ″ 115˜ 119
 15 ″
Figure USRE037979-20030204-C00020
Figure USRE037979-20030204-C00021
 		″ ″ ″ 95˜97
 16 ″
Figure USRE037979-20030204-C00022
Figure USRE037979-20030204-C00023
 		″ ″ ″ 175˜ 176
 17 ″ ″
Figure USRE037979-20030204-C00024
 		″ ″ ″ 148˜ 150
 18 ″ ″
Figure USRE037979-20030204-C00025
 		″ ″ ″ 157˜ 159
 19 ″
Figure USRE037979-20030204-C00026
Figure USRE037979-20030204-C00027
 		″ ″ ″ 107˜ 109
 20 ″ ″
Figure USRE037979-20030204-C00028
 		″ ″ ″ 102˜ 104
 21 —CH3
Figure USRE037979-20030204-C00029
Figure USRE037979-20030204-C00030
 		—H O O 74˜80
 22 ″ ″
Figure USRE037979-20030204-C00031
 		″ ″ ″ 148˜ 150
 23 ″ ″
Figure USRE037979-20030204-C00032
 		″ ″ ″ 133˜ 134
 24 ″ ″
Figure USRE037979-20030204-C00033
 		″ ″ ″ 91˜92
 25 ″ ″
Figure USRE037979-20030204-C00034
 		″ ″ ″ 136˜ 137
 26 ″ ″
Figure USRE037979-20030204-C00035
 		″ ″ ″ 123˜ 124
 27 ″ ″
Figure USRE037979-20030204-C00036
 		″ ″ ″ 238˜ 242
 28 ″ ″
Figure USRE037979-20030204-C00037
 		″ ″ ″ 229˜ 230
 29 ″ ″
Figure USRE037979-20030204-C00038
 		″ ″ ″ 158˜ 160
 30 ″ ″
Figure USRE037979-20030204-C00039
 		″ ″ ″ 124˜ 127
 31 ″ ″
Figure USRE037979-20030204-C00040
 		″ ″ ″ 157˜ 158
 32 —CH3
Figure USRE037979-20030204-C00041
Figure USRE037979-20030204-C00042
 		—H O O 159˜ 161
 33 ″ ″
Figure USRE037979-20030204-C00043
Figure USRE037979-20030204-C00044
 		″ ″ Oil
 34 ″ ″
Figure USRE037979-20030204-C00045
 		—CH3 ″ ″ 74˜75
 35 ″ ″
Figure USRE037979-20030204-C00046
 		—H ″ ″
 36 ″ ″
Figure USRE037979-20030204-C00047
 		″ ″ ″
 37 ″ ″
Figure USRE037979-20030204-C00048
 		″ ″ ″
 38 ″ ″
Figure USRE037979-20030204-C00049
 		″ ″ ″
 39 ″ ″
Figure USRE037979-20030204-C00050
 		″ ″ ″
 40 ″ ″
Figure USRE037979-20030204-C00051
 		″ ″ ″
 41 ″ ″
Figure USRE037979-20030204-C00052
 		″ ″ ″ 136˜ 138
 42 ″ ″
Figure USRE037979-20030204-C00053
 		″ ″ S
 43 —CH3
Figure USRE037979-20030204-C00054
Figure USRE037979-20030204-C00055
 		—CH3 O S
 44 ″ ″
Figure USRE037979-20030204-C00056
 		—H ″ ″
 45 ″ ″
Figure USRE037979-20030204-C00057
 		″ ″ ″
 46 ″ ″
Figure USRE037979-20030204-C00058
 		″ ″ ″
 47 ″ ″
Figure USRE037979-20030204-C00059
 		″ ″ ″
 48 ″ ″
Figure USRE037979-20030204-C00060
 		″ ″ ″
 49 ″ ″
Figure USRE037979-20030204-C00061
 		″ ″ ″
 50 ″ ″
Figure USRE037979-20030204-C00062
 		″ ″ ″
 51 ″ ″
Figure USRE037979-20030204-C00063
 		″ ″ ″
 52 ″ ″
Figure USRE037979-20030204-C00064
 		″ ″ ″
 53 ″ ″
Figure USRE037979-20030204-C00065
 		″ ″ ″
 54 —CH3
Figure USRE037979-20030204-C00066
Figure USRE037979-20030204-C00067
 		—H O S
 55 ″ ″
Figure USRE037979-20030204-C00068
 		″ ″ ″
 56 ″ ″
Figure USRE037979-20030204-C00069
 		″ ″ ″
 57 ″ ″
Figure USRE037979-20030204-C00070
 		″ ″ ″
 58 ″ ″
Figure USRE037979-20030204-C00071
 		″ ″ ″
 59 ″ ″
Figure USRE037979-20030204-C00072
 		″ ″ ″
 60 ″ ″
Figure USRE037979-20030204-C00073
 		″ ″ ″
 61 ″ ″
Figure USRE037979-20030204-C00074
 		″ ″ ″
 62 ″ ″
Figure USRE037979-20030204-C00075
 		″ ″ ″
 63 ″ ″
Figure USRE037979-20030204-C00076
 		″ ″ ″
 64 ″ ″
Figure USRE037979-20030204-C00077
 		″ ″ ″
 65 —CH3
Figure USRE037979-20030204-C00078
Figure USRE037979-20030204-C00079
 		—H O S
 66 ″ ″
Figure USRE037979-20030204-C00080
 		″ ″ O
 67 ″
Figure USRE037979-20030204-C00081
Figure USRE037979-20030204-C00082
 		″ ″ ″
 68 ″ ″
Figure USRE037979-20030204-C00083
Figure USRE037979-20030204-C00084
 		″ ″
 69 ″ ″
Figure USRE037979-20030204-C00085
 		—H ″ ″
 70 ″ ″
Figure USRE037979-20030204-C00086
 		″ ″ ″
 71 ″ ″
Figure USRE037979-20030204-C00087
 		″ ″ ″
 72 ″ ″
Figure USRE037979-20030204-C00088
 		″ ″ ″
 73 ″ ″
Figure USRE037979-20030204-C00089
 		″ ″ ″
 74 ″ ″
Figure USRE037979-20030204-C00090
 		″ ″ ″
 75 ″ ″
Figure USRE037979-20030204-C00091
 		″ ″ ″
 76 —CH3
Figure USRE037979-20030204-C00092
Figure USRE037979-20030204-C00093
 		—H O O
 77 ″ ″
Figure USRE037979-20030204-C00094
 		″ ″ ″
 78 ″ ″
Figure USRE037979-20030204-C00095
 		″ ″ ″
 79 ″ ″
Figure USRE037979-20030204-C00096
 		″ ″ ″
 80 ″ ″
Figure USRE037979-20030204-C00097
 		″ ″ ″
 81 ″ ″
Figure USRE037979-20030204-C00098
 		″ ″ ″
 82 ″ ″
Figure USRE037979-20030204-C00099
 		″ ″ ″
 83 ″ ″
Figure USRE037979-20030204-C00100
 		″ ″ ″
 84 ″ ″
Figure USRE037979-20030204-C00101
 		″ ″ ″
 85 ″ ″
Figure USRE037979-20030204-C00102
 		″ ″ ″
 86 ″ ″
Figure USRE037979-20030204-C00103
 		″ ″ ″
 87 —CH3
Figure USRE037979-20030204-C00104
Figure USRE037979-20030204-C00105
 		—H O O
 88 ″ ″
Figure USRE037979-20030204-C00106
 		″ ″ ″
 89 ″ ″
Figure USRE037979-20030204-C00107
 		″ ″ ″
 90 ″ ″
Figure USRE037979-20030204-C00108
 		″ ″ ″
 91 ″ ″
Figure USRE037979-20030204-C00109
 		″ ″ ″
 92 ″ ″
Figure USRE037979-20030204-C00110
 		″ ″ ″
 93 ″ ″
Figure USRE037979-20030204-C00111
 		″ ″ ″
 94 ″ ″
Figure USRE037979-20030204-C00112
 		″ ″ ″
 95 ″
Figure USRE037979-20030204-C00113
Figure USRE037979-20030204-C00114
 		″ ″ ″
 96 ″ ″
Figure USRE037979-20030204-C00115
 		″ ″ ″
 97 ″ ″
Figure USRE037979-20030204-C00116
 		″ ″ ″
 98 —CH3
Figure USRE037979-20030204-C00117
Figure USRE037979-20030204-C00118
 		—H O O
 99 ″ ″
Figure USRE037979-20030204-C00119
 		″ ″ ″
100 ″ ″
Figure USRE037979-20030204-C00120
 		″ ″ ″
101 ″ ″
Figure USRE037979-20030204-C00121
 		″ ″ ″
102 ″ ″
Figure USRE037979-20030204-C00122
 		″ ″ ″
103 ″ ″
Figure USRE037979-20030204-C00123
 		″ ″ ″
104 ″ ″
Figure USRE037979-20030204-C00124
 		″ ″ ″
105 ″ ″
Figure USRE037979-20030204-C00125
 		″ ″ ″
106 ″ ″
Figure USRE037979-20030204-C00126
 		″ ″ ″
107 ″ ″
Figure USRE037979-20030204-C00127
 		″ ″ ″
108 ″ ″
Figure USRE037979-20030204-C00128
 		″ ″ ″
109 —CH3
Figure USRE037979-20030204-C00129
Figure USRE037979-20030204-C00130
 		—H O O
110 ″ ″
Figure USRE037979-20030204-C00131
 		″ ″ ″
111 ″ ″
Figure USRE037979-20030204-C00132
 		″ ″ ″
112 ″ ″
Figure USRE037979-20030204-C00133
 		″ ″ ″
113 ″ ″
Figure USRE037979-20030204-C00134
 		″ ″ ″
114 ″ ″
Figure USRE037979-20030204-C00135
 		″ ″ ″
115 ″ ″
Figure USRE037979-20030204-C00136
 		″ ″ ″
116 ″ ″
Figure USRE037979-20030204-C00137
 		″ ″ ″
117 ″ ″
Figure USRE037979-20030204-C00138
 		″ ″ ″
118 ″ ″
Figure USRE037979-20030204-C00139
 		″ ″ ″
119 ″ ″
Figure USRE037979-20030204-C00140
 		″ ″ ″
120 —CH3
Figure USRE037979-20030204-C00141
Figure USRE037979-20030204-C00142
 		—H O O
121 ″ ″
Figure USRE037979-20030204-C00143
 		″ ″ ″
122 ″ ″
Figure USRE037979-20030204-C00144
 		″ ″ ″
123 ″
Figure USRE037979-20030204-C00145
Figure USRE037979-20030204-C00146
 		″ ″ S
124 ″ ″
Figure USRE037979-20030204-C00147
 		″ ″ ″
125 ″ ″
Figure USRE037979-20030204-C00148
 		″ ″ ″
126 ″ ″
Figure USRE037979-20030204-C00149
 		″ ″ ″
127 ″ ″
Figure USRE037979-20030204-C00150
 		″ ″ ″
128 ″ ″
Figure USRE037979-20030204-C00151
 		″ ″ ″
129 ″ ″
Figure USRE037979-20030204-C00152
 		″ ″ ″
130 ″ ″
Figure USRE037979-20030204-C00153
 		″ ″ ″
131 —CH3
Figure USRE037979-20030204-C00154
Figure USRE037979-20030204-C00155
 		—H O S
132 ″ ″
Figure USRE037979-20030204-C00156
 		″ ″ ″
133 ″ ″
Figure USRE037979-20030204-C00157
 		″ ″ ″
134 ″ ″
Figure USRE037979-20030204-C00158
 		″ ″ ″
135 ″ ″
Figure USRE037979-20030204-C00159
 		″ ″ ″
136 ″ ″
Figure USRE037979-20030204-C00160
 		″ ″ ″
137 ″ ″
Figure USRE037979-20030204-C00161
 		″ ″ ″
138 ″ ″
Figure USRE037979-20030204-C00162
 		″ ″ ″
139 ″ ″
Figure USRE037979-20030204-C00163
 		″ ″ ″
140 ″ ″
Figure USRE037979-20030204-C00164
 		″ ″ ″
141 ″ ″
Figure USRE037979-20030204-C00165
 		″ ″ ″
142 —CH3
Figure USRE037979-20030204-C00166
Figure USRE037979-20030204-C00167
 		—H O S
143 ″ ″
Figure USRE037979-20030204-C00168
 		″ ″ ″
144 ″ ″
Figure USRE037979-20030204-C00169
 		″ ″ ″
145 ″ ″
Figure USRE037979-20030204-C00170
 		″ ″ ″
146 ″ ″
Figure USRE037979-20030204-C00171
 		″ ″ ″
147 ″ ″
Figure USRE037979-20030204-C00172
 		″ ″ ″
148 ″ ″
Figure USRE037979-20030204-C00173
 		″ ″ ″
149 ″ ″
Figure USRE037979-20030204-C00174
 		″ ″ ″
150 ″
Figure USRE037979-20030204-C00175
Figure USRE037979-20030204-C00176
 		″ ″ ″
151 ″ ″
Figure USRE037979-20030204-C00177
 		″ ″ ″
152 ″ ″
Figure USRE037979-20030204-C00178
 		″ ″ ″
153 —CH3
Figure USRE037979-20030204-C00179
Figure USRE037979-20030204-C00180
 		—H O S
154 ″ ″
Figure USRE037979-20030204-C00181
 		″ ″ ″
155 ″ ″
Figure USRE037979-20030204-C00182
 		″ ″ ″
156 ″ ″
Figure USRE037979-20030204-C00183
 		″ ″ ″
157 ″ ″
Figure USRE037979-20030204-C00184
 		″ ″ ″
158 ″ ″
Figure USRE037979-20030204-C00185
 		″ ″ ″
159 ″ ″
Figure USRE037979-20030204-C00186
 		″ ″ ″
160 ″ ″
Figure USRE037979-20030204-C00187
 		″ ″ ″
161 ″ ″
Figure USRE037979-20030204-C00188
 		″ ″ ″
162 ″ ″
Figure USRE037979-20030204-C00189
 		″ ″ ″
163 ″
Figure USRE037979-20030204-C00190
Figure USRE037979-20030204-C00191
 		″ ″ O
164 —CH3
Figure USRE037979-20030204-C00192
Figure USRE037979-20030204-C00193
 		—H O O
165 ″ ″
Figure USRE037979-20030204-C00194
 		″ ″ ″
166 ″ ″
Figure USRE037979-20030204-C00195
 		″ ″ ″
167 ″ ″
Figure USRE037979-20030204-C00196
 		″ ″ ″
168 ″ ″
Figure USRE037979-20030204-C00197
 		″ ″ ″
169 ″ ″
Figure USRE037979-20030204-C00198
 		″ ″ ″
170 ″ ″
Figure USRE037979-20030204-C00199
 		″ ″ ″
171 ″ ″
Figure USRE037979-20030204-C00200
 		″ ″ ″
172 ″ ″
Figure USRE037979-20030204-C00201
 		″ ″ ″
173 ″ ″
Figure USRE037979-20030204-C00202
 		″ ″ ″
174 ″ ″
Figure USRE037979-20030204-C00203
 		″ ″ ″
175 —CH3
Figure USRE037979-20030204-C00204
Figure USRE037979-20030204-C00205
 		—H O O
176 ″ ″
Figure USRE037979-20030204-C00206
 		″ ″ ″
177 ″ ″
Figure USRE037979-20030204-C00207
 		″ ″ ″
178 ″ ″
Figure USRE037979-20030204-C00208
 		″ ″ ″
179 ″ ″
Figure USRE037979-20030204-C00209
 		″ ″ ″
180 ″ ″
Figure USRE037979-20030204-C00210
 		″ ″ ″
181 ″ ″
Figure USRE037979-20030204-C00211
 		″ ″ ″
182 ″ ″
Figure USRE037979-20030204-C00212
 		″ ″ ″
183 ″
Figure USRE037979-20030204-C00213
Figure USRE037979-20030204-C00214
 		″ ″ ″
184 ″ ″
Figure USRE037979-20030204-C00215
 		″ ″ ″
185 ″ ″
Figure USRE037979-20030204-C00216
 		″ ″ ″
186 —CH3
Figure USRE037979-20030204-C00217
Figure USRE037979-20030204-C00218
 		—H O O
187 ″ ″
Figure USRE037979-20030204-C00219
 		″ ″ ″
188 ″ ″
Figure USRE037979-20030204-C00220
 		″ ″ ″
189 ″ ″
Figure USRE037979-20030204-C00221
 		″ ″ ″
190 ″ ″
Figure USRE037979-20030204-C00222
 		″ ″ ″
191 ″ ″
Figure USRE037979-20030204-C00223
 		″ ″ ″
192 ″ ″
Figure USRE037979-20030204-C00224
 		″ ″ ″
193 ″ ″
Figure USRE037979-20030204-C00225
 		″ ″ ″
194 ″ ″
Figure USRE037979-20030204-C00226
 		″ ″ ″
195 ″ ″
Figure USRE037979-20030204-C00227
 		″ ″ ″
196 ″ ″
Figure USRE037979-20030204-C00228
 		″ ″ ″
197 —CH3
Figure USRE037979-20030204-C00229
Figure USRE037979-20030204-C00230
 		—H O O
198 ″ ″
Figure USRE037979-20030204-C00231
 		″ ″ ″
199 ″ ″
Figure USRE037979-20030204-C00232
 		″ ″ ″
200 ″ ″
Figure USRE037979-20030204-C00233
 		″ ″ ″
201 ″ ″
Figure USRE037979-20030204-C00234
 		″ ″ ″
202 ″
Figure USRE037979-20030204-C00235
Figure USRE037979-20030204-C00236
 		″ ″ ″
203 ″ ″
Figure USRE037979-20030204-C00237
 		″ ″ ″
204 ″ ″
Figure USRE037979-20030204-C00238
 		″ ″ ″
205 ″ ″
Figure USRE037979-20030204-C00239
 		″ ″ ″
206 ″ ″
Figure USRE037979-20030204-C00240
 		″ ″ ″
207 ″ ″
Figure USRE037979-20030204-C00241
 		″ ″ ″
208 —CH3
Figure USRE037979-20030204-C00242
Figure USRE037979-20030204-C00243
 		—H O O
209 ″ ″
Figure USRE037979-20030204-C00244
 		″ ″ ″
210 ″ ″
Figure USRE037979-20030204-C00245
 		″ ″ ″
211 ″ ″
Figure USRE037979-20030204-C00246
 		″ ″ ″
212 ″ ″
Figure USRE037979-20030204-C00247
 		″ ″ ″
213 ″ ″
Figure USRE037979-20030204-C00248
 		″ ″ ″
214 ″ ″
Figure USRE037979-20030204-C00249
 		″ ″ ″
215 ″ ″
Figure USRE037979-20030204-C00250
 		″ ″ ″
216 ″ ″
Figure USRE037979-20030204-C00251
 		″ ″ ″
217 ″ ″
Figure USRE037979-20030204-C00252
 		″ ″ ″
218 ″ ″
Figure USRE037979-20030204-C00253
 		″ ″ ″
219 —CH3
Figure USRE037979-20030204-C00254
Figure USRE037979-20030204-C00255
 		—H O O
220 ″ ″
Figure USRE037979-20030204-C00256
 		″ ″ ″
221 ″ ″
Figure USRE037979-20030204-C00257
 		″ ″ ″
222 ″ ″
Figure USRE037979-20030204-C00258
 		″ ″ ″
223 ″
Figure USRE037979-20030204-C00259
Figure USRE037979-20030204-C00260
 		—CH3 ″ S
224 ″ ″
Figure USRE037979-20030204-C00261
Figure USRE037979-20030204-C00262
 		″ ″
225 ″ ″
Figure USRE037979-20030204-C00263
 		—CH3 ″ ″
226 ″ ″
Figure USRE037979-20030204-C00264
 		″ ″ ″
227 ″ ″
Figure USRE037979-20030204-C00265
 		″ ″ ″
228 ″ ″
Figure USRE037979-20030204-C00266
 		″ ″ ″
229 ″
Figure USRE037979-20030204-C00267
Figure USRE037979-20030204-C00268
 		″ ″ ″
230 —CH3
Figure USRE037979-20030204-C00269
Figure USRE037979-20030204-C00270
Figure USRE037979-20030204-C00271
 		O S
231 ″ ″
Figure USRE037979-20030204-C00272
 		″ ″ ″
232 ″ ″
Figure USRE037979-20030204-C00273
 		″ ″ ″
233 ″ ″
Figure USRE037979-20030204-C00274
 		″ ″ ″
234 ″ ″
Figure USRE037979-20030204-C00275
 		—CH3 ″ ″
235 ″ ″
Figure USRE037979-20030204-C00276
Figure USRE037979-20030204-C00277
 		″ ″
236 —C2H5
Figure USRE037979-20030204-C00278
Figure USRE037979-20030204-C00279
 		—H ″ O
237 ″ ″
Figure USRE037979-20030204-C00280
 		″ ″ ″
238 ″ ″
Figure USRE037979-20030204-C00281
 		″ ″ ″
239 ″ ″
Figure USRE037979-20030204-C00282
 		″ ″ ″
240 ″ ″
Figure USRE037979-20030204-C00283
 		″ ″ ″
241 —C2H5
Figure USRE037979-20030204-C00284
Figure USRE037979-20030204-C00285
 		—H O O
242 ″ ″
Figure USRE037979-20030204-C00286
 		″ ″ ″
243 ″ ″
Figure USRE037979-20030204-C00287
 		″ ″ ″
244 ″ ″
Figure USRE037979-20030204-C00288
 		″ ″ ″
245 ″ ″
Figure USRE037979-20030204-C00289
 		″ ″ ″
246 ″ ″
Figure USRE037979-20030204-C00290
 		″ ″ ″
247 ″ ″
Figure USRE037979-20030204-C00291
 		″ ″ ″ 123˜ 125
248 ″ ″
Figure USRE037979-20030204-C00292
 		″ ″ ″
249 ″ ″
Figure USRE037979-20030204-C00293
 		″ ″ ″
250 ″ ″
Figure USRE037979-20030204-C00294
 		″ ″ ″
251 ″ ″
Figure USRE037979-20030204-C00295
 		″ ″ ″
252 —C2H5
Figure USRE037979-20030204-C00296
Figure USRE037979-20030204-C00297
 		—H O O 107˜ 108
253 ″ ″
Figure USRE037979-20030204-C00298
 		″ ″ ″
254 ″ ″
Figure USRE037979-20030204-C00299
 		″ ″ ″
255 ″ ″
Figure USRE037979-20030204-C00300
 		″ ″ ″
256 ″ ″
Figure USRE037979-20030204-C00301
 		—CH3 ″ ″
257 ″ ″
Figure USRE037979-20030204-C00302
Figure USRE037979-20030204-C00303
 		″ ″
258 ″ ″
Figure USRE037979-20030204-C00304
 		—CH3 ″ ″
259 ″ ″
Figure USRE037979-20030204-C00305
 		″ ″ ″
260 ″
Figure USRE037979-20030204-C00306
Figure USRE037979-20030204-C00307
 		H ″ S
261 ″ ″
Figure USRE037979-20030204-C00308
 		″ ″ O
262 ″ ″
Figure USRE037979-20030204-C00309
 		—CH3 ″ S
263 —C2H5
Figure USRE037979-20030204-C00310
Figure USRE037979-20030204-C00311
 		—H O S
264 ″ ″
Figure USRE037979-20030204-C00312
 		″ ″ ″
265 ″ ″
Figure USRE037979-20030204-C00313
 		—CH3 ″ ″
266 —CH═CHBr
Figure USRE037979-20030204-C00314
Figure USRE037979-20030204-C00315
 		H ″ ″
267 ″ ″
Figure USRE037979-20030204-C00316
 		″ ″ O
268 ″ ″
Figure USRE037979-20030204-C00317
 		″ ″ ″
269 ″ ″
Figure USRE037979-20030204-C00318
 		″ ″ ″
270 ″ ″
Figure USRE037979-20030204-C00319
 		″ ″ ″ 143˜ 148
271 ″ ″
Figure USRE037979-20030204-C00320
 		″ ″ S
272 ″ ″
Figure USRE037979-20030204-C00321
 		″ ″ ″
273 ″ ″
Figure USRE037979-20030204-C00322
 		″ ″ ″
274 —CH═CHBr
Figure USRE037979-20030204-C00323
Figure USRE037979-20030204-C00324
 		—H O S
275 ″ ″
Figure USRE037979-20030204-C00325
 		—CH3 ″ ″
276 ″
Figure USRE037979-20030204-C00326
Figure USRE037979-20030204-C00327
 		H ″ O
277 ″ ″
Figure USRE037979-20030204-C00328
 		″ ″ ″
278 —CH3
Figure USRE037979-20030204-C00329
Figure USRE037979-20030204-C00330
 		″ ″ S
279 ″ ″
Figure USRE037979-20030204-C00331
 		″ ″ O
280 ″ ″ ″
Figure USRE037979-20030204-C00332
 		″ S
281 ″ ″
Figure USRE037979-20030204-C00333
 		H ″ ″
282 ″
Figure USRE037979-20030204-C00334
Figure USRE037979-20030204-C00335
 		″ ″ O
283 ″ ″
Figure USRE037979-20030204-C00336
 		″ ″ ″
284 ″ ″
Figure USRE037979-20030204-C00337
 		″ ″ ″
285 —CH3
Figure USRE037979-20030204-C00338
Figure USRE037979-20030204-C00339
 		—CH3 O O
286 ″
Figure USRE037979-20030204-C00340
Figure USRE037979-20030204-C00341
 		H ″ ″
287 ″ ″
Figure USRE037979-20030204-C00342
 		″ ″ ″
288 ″
Figure USRE037979-20030204-C00343
Figure USRE037979-20030204-C00344
 		″ ″ S
289 ″ ″
Figure USRE037979-20030204-C00345
 		″ ″ ″
290 ″ ″
Figure USRE037979-20030204-C00346
 		—CH3 ″ ″
291 ″
Figure USRE037979-20030204-C00347
Figure USRE037979-20030204-C00348
 		H ″ ″
292 ″ ″
Figure USRE037979-20030204-C00349
 		″ ″ ″
293 ″ ″
Figure USRE037979-20030204-C00350
 		″ ″ ″
294 ″
Figure USRE037979-20030204-C00351
Figure USRE037979-20030204-C00352
 		″ ″ O
295 ″ ″
Figure USRE037979-20030204-C00353
 		″ ″ ″
296 —CH3
Figure USRE037979-20030204-C00354
Figure USRE037979-20030204-C00355
 		—H O O
297 ″ ″
Figure USRE037979-20030204-C00356
 		″ ″ ″
298 ″ ″
Figure USRE037979-20030204-C00357
 		″ ″ S
299 ″ ″
Figure USRE037979-20030204-C00358
 		″ ″ ″
300 ″
Figure USRE037979-20030204-C00359
Figure USRE037979-20030204-C00360
 		″ ″ ″
301 ″ ″
Figure USRE037979-20030204-C00361
 		″ ″ ″
302 ″ ″
Figure USRE037979-20030204-C00362
 		″ ″ ″
303 ″ ″
Figure USRE037979-20030204-C00363
 		″ ″ ″
304 ″
Figure USRE037979-20030204-C00364
Figure USRE037979-20030204-C00365
 		″ ″ O
305 ″ ″
Figure USRE037979-20030204-C00366
 		″ ″ ″
306 ″ ″
Figure USRE037979-20030204-C00367
 		″ ″ ″
307 —CH3
Figure USRE037979-20030204-C00368
Figure USRE037979-20030204-C00369
 		—H O O
308 ″ ″
Figure USRE037979-20030204-C00370
 		″ ″ ″
309 ″ ″
Figure USRE037979-20030204-C00371
 		″ ″ ″
310 ″ ″
Figure USRE037979-20030204-C00372
 		″ ″ S
311 ″ ″
Figure USRE037979-20030204-C00373
 		″ ″ ″
312 ″
Figure USRE037979-20030204-C00374
Figure USRE037979-20030204-C00375
 		″ ″ ″
313 ″ ″
Figure USRE037979-20030204-C00376
 		″ ″ ″
314 ″ ″
Figure USRE037979-20030204-C00377
 		″ ″ ″
315 ″ ″
Figure USRE037979-20030204-C00378
 		″ ″ ″
316 ″ ″
Figure USRE037979-20030204-C00379
 		″ ″ ″
317 ″ ″
Figure USRE037979-20030204-C00380
 		″ ″ ″
318 —CH3
Figure USRE037979-20030204-C00381
Figure USRE037979-20030204-C00382
 		—H O S
319 ″ ″
Figure USRE037979-20030204-C00383
 		″ ″ ″
320 ″
Figure USRE037979-20030204-C00384
Figure USRE037979-20030204-C00385
 		″ ″ ″
321 ″ ″
Figure USRE037979-20030204-C00386
 		″ ″ ″
322 ″ ″
Figure USRE037979-20030204-C00387
 		″ ″ ″
323 ″ ″
Figure USRE037979-20030204-C00388
 		″ ″ ″
324 ″ ″
Figure USRE037979-20030204-C00389
 		″ ″ ″
325 ″ ″
Figure USRE037979-20030204-C00390
 		″ ″ ″
326 ″ ″
Figure USRE037979-20030204-C00391
 		″ ″ ″
327 ″ ″
Figure USRE037979-20030204-C00392
 		″ ″ ″
328 ″
Figure USRE037979-20030204-C00393
Figure USRE037979-20030204-C00394
 		″ ″ O
329 —CH3
Figure USRE037979-20030204-C00395
Figure USRE037979-20030204-C00396
 		—H O S
330 ″ ″
Figure USRE037979-20030204-C00397
 		″ ″ ″
331 ″ ″
Figure USRE037979-20030204-C00398
 		″ ″ ″
332 ″ ″
Figure USRE037979-20030204-C00399
 		″ ″ ″
333 ″ ″
Figure USRE037979-20030204-C00400
 		″ ″ ″
334 ″ ″
Figure USRE037979-20030204-C00401
 		″ ″ ″
335 ″ ″
Figure USRE037979-20030204-C00402
 		″ ″ ″
336 ″ ″
Figure USRE037979-20030204-C00403
 		″ ″ ″
337 ″ ″
Figure USRE037979-20030204-C00404
 		″ ″ ″
338 ″ ″
Figure USRE037979-20030204-C00405
 		″ ″ ″
339 ″ ″
Figure USRE037979-20030204-C00406
 		″ ″ ″
340 —CH3
Figure USRE037979-20030204-C00407
Figure USRE037979-20030204-C00408
 		—H O S
341 ″
Figure USRE037979-20030204-C00409
Figure USRE037979-20030204-C00410
 		″ ″ ″
342 ″
Figure USRE037979-20030204-C00411
Figure USRE037979-20030204-C00412
 		″ ″ ″
343 ″ ″
Figure USRE037979-20030204-C00413
 		″ ″ ″
344 ″ ″
Figure USRE037979-20030204-C00414
 		″ ″ ″
345 ″ ″
Figure USRE037979-20030204-C00415
 		″ ″ ″
346 —C2H5
Figure USRE037979-20030204-C00416
Figure USRE037979-20030204-C00417
 		″ ″ ″
347 ″ ″
Figure USRE037979-20030204-C00418
 		″ ″ ″
348 ″ ″
Figure USRE037979-20030204-C00419
 		″ ″ ″
349 ″ ″
Figure USRE037979-20030204-C00420
 		″ ″ ″
350 ″ ″
Figure USRE037979-20030204-C00421
 		″ ″ ″
351 —CH═CHBr
Figure USRE037979-20030204-C00422
Figure USRE037979-20030204-C00423
 		—H O S
352 ″ ″
Figure USRE037979-20030204-C00424
 		″ ″ ″
353 ″ ″
Figure USRE037979-20030204-C00425
 		″ ″ ″
354 ″ ″
Figure USRE037979-20030204-C00426
 		″ ″ ″
355 ″ ″
Figure USRE037979-20030204-C00427
 		″ ″ ″
356 ″ ″
Figure USRE037979-20030204-C00428
 		″ ″ ″
357 —C2H5
Figure USRE037979-20030204-C00429
Figure USRE037979-20030204-C00430
 		″ ″ O 165˜ 166
358 ″
Figure USRE037979-20030204-C00431
 		″ ″ ″ S 106˜ 109
359 ″
Figure USRE037979-20030204-C00432
 		″ ″ ″ ″ 155˜ 156
360 ″
Figure USRE037979-20030204-C00433
Figure USRE037979-20030204-C00434
 		″ ″ O 110˜ 112
361 ″
Figure USRE037979-20030204-C00435
 		″ ″ ″ ″ 156˜ 158
362 —CH3
Figure USRE037979-20030204-C00436
Figure USRE037979-20030204-C00437
 		—H O O 157˜ 161
363 —C2H5 ″ ″ ″ ″ S 151˜ 153
364 ″
Figure USRE037979-20030204-C00438
 		″ ″ ″ ″ 158˜ 160
365 ″
Figure USRE037979-20030204-C00439
Figure USRE037979-20030204-C00440
 		″ ″ O 159˜ 162
366 ″ ″ ″ ″ ″ S 112˜ 116
367 ″ ″
Figure USRE037979-20030204-C00441
 		″ ″ O
368 ″ ″ ″ ″ ″ S
369 ″
Figure USRE037979-20030204-C00442
Figure USRE037979-20030204-C00443
 		″ ″ O
370 ″
Figure USRE037979-20030204-C00444
 		″ ″ ″ ″
371 ″
Figure USRE037979-20030204-C00445
 		″ ″ ″ ″
372 —C2H5
Figure USRE037979-20030204-C00446
Figure USRE037979-20030204-C00447
 		—H O S 157˜ 160
373 ″
Figure USRE037979-20030204-C00448
 		″ ″ ″ ″
374 ″
Figure USRE037979-20030204-C00449
 		″ ″ ″ ″
375 ″
Figure USRE037979-20030204-C00450
Figure USRE037979-20030204-C00451
 		″ ″ O
376 ″ ″ ″ ″ ″ S
377 ″ ″
Figure USRE037979-20030204-C00452
 		″ ″ O
378 ″ ″ ″ ″ ″ S
379 —CH3
Figure USRE037979-20030204-C00453
Figure USRE037979-20030204-C00454
 		″ ″ ″
380 ″
Figure USRE037979-20030204-C00455
 		″ ″ ″ O
381 ″ ″ ″ ″ ″ S
382 —CH3
Figure USRE037979-20030204-C00456
Figure USRE037979-20030204-C00457
 		—H O O
383 ″ ″ ″ ″ ″ S
384 ″
Figure USRE037979-20030204-C00458
 		″ ″ ″ O
385 ″ ″ ″ ″ ″ S
386 ″
Figure USRE037979-20030204-C00459
 		″ ″ ″ O
387 ″ ″ ″ ″ ″ S
388 ″
Figure USRE037979-20030204-C00460
 		″ ″ ″ O
389 ″ ″ ″ ″ ″ S
390 ″
Figure USRE037979-20030204-C00461
 		″ ″ ″ O
391 ″ ″ ″ ″ ″ S
392 ″
Figure USRE037979-20030204-C00462
Figure USRE037979-20030204-C00463
 		″ ″ ″
393 ″
Figure USRE037979-20030204-C00464
Figure USRE037979-20030204-C00465
 		″ ″ ″
394 ″
Figure USRE037979-20030204-C00466
 		″ ″ ″ ″
395 ″
Figure USRE037979-20030204-C00467
 		″ ″ ″ O
396 ″ ″ ″ ″ ″ S
397 ″
Figure USRE037979-20030204-C00468
Figure USRE037979-20030204-C00469
 		″ ″ ″
398 ″ ″ ″ ″ ″ O
399 ″
Figure USRE037979-20030204-C00470
Figure USRE037979-20030204-C00471
 		″ ″ S
400 ″ ″
Figure USRE037979-20030204-C00472
 		″ ″ ″
401 ″
Figure USRE037979-20030204-C00473
Figure USRE037979-20030204-C00474
 		″ ″ O
402 ″ ″ ″ ″ ″ S
403 ″ ″
Figure USRE037979-20030204-C00475
 		″ ″ O
404 —CH3
Figure USRE037979-20030204-C00476
Figure USRE037979-20030204-C00477
 		—H O S
405 ″
Figure USRE037979-20030204-C00478
Figure USRE037979-20030204-C00479
 		″ ″ ″
406 ″
Figure USRE037979-20030204-C00480
 		″ ″ ″ ″
407 ″
Figure USRE037979-20030204-C00481
 		″ ″ ″ ″
408 ″
Figure USRE037979-20030204-C00482
 		″ ″ ″ O
409 ″ ″ ″ ″ ″ S
410 ″
Figure USRE037979-20030204-C00483
Figure USRE037979-20030204-C00484
 		″ ″ O
411 ″
Figure USRE037979-20030204-C00485
 		″ ″ ″ S
412 ″
Figure USRE037979-20030204-C00486
 		″ ″ ″ ″
413 ″
Figure USRE037979-20030204-C00487
 		″ ″ ″ O
414 ″ ″ ″ ″ ″ S
415 —CH3
Figure USRE037979-20030204-C00488
Figure USRE037979-20030204-C00489
 		—H O S
416 ″
Figure USRE037979-20030204-C00490
 		″ ″ ″ ″
417 ″
Figure USRE037979-20030204-C00491
 		″ ″ ″ ″
418 ″
Figure USRE037979-20030204-C00492
 		″ ″ ″ O
419 ″ ″ ″ ″ ″ S
420 ″
Figure USRE037979-20030204-C00493
Figure USRE037979-20030204-C00494
 		″ ″ O
421 ″ ″ ″ ″ ″ S
422 —C2H5 ″ ″ ″ ″ O
423 ″ ″ ″ ″ ″ S
424 —CH3
Figure USRE037979-20030204-C00495
 		″ ″ ″ O
425 ″ ″ ″ ″ ″ S
426 —C2H5
Figure USRE037979-20030204-C00496
Figure USRE037979-20030204-C00497
 		—H O O
427 ″ ″ ″ ″ ″ S
428 —CH3
Figure USRE037979-20030204-C00498
 		″ ″ ″ O
429 ″ ″ ″ ″ ″ S
430 —C2H5 ″ ″ ″ ″ O
431 ″
Figure USRE037979-20030204-C00499
 		″ ″ ″ S
432 —CH3
Figure USRE037979-20030204-C00500
 		″ ″ ″ O
433 ″ ″ ″ ″ ″ S
434 —C2H5 ″ ″ ″ ″ O
435 ″ ″ ″ ″ ″ S
436 —CH3
Figure USRE037979-20030204-C00501
 		″ ″ ″ O
437 —CH3
Figure USRE037979-20030204-C00502
Figure USRE037979-20030204-C00503
 		—H O S
438 —C2H5 ″ ″ ″ ″ O
439 ″ ″ ″ ″ ″ S
440 —CH3
Figure USRE037979-20030204-C00504
 		″ ″ ″ O
441 ″ ″ ″ ″ ″ S
442 —C2H5
Figure USRE037979-20030204-C00505
 		″ ″ ″ O
443 ″ ″ ″ ″ ″ S
444 —CH3
Figure USRE037979-20030204-C00506
 		″ ″ ″ O
445 ″ ″ ″ ″ ″ S
445 —C2H5 ″ ″ ″ ″ O
447 ″ ″ ″ ″ ″ S
448 —C2H5
Figure USRE037979-20030204-C00507
Figure USRE037979-20030204-C00508
 		—H O S
449 ″
Figure USRE037979-20030204-C00509
 		″ ″ ″ O
450 ″ ″ ″ ″ ″ S
451 ″
Figure USRE037979-20030204-C00510
 		″ ″ ″ O
452 ″ ″ ″ ″ ″ S
453 ″
Figure USRE037979-20030204-C00511
 		″ ″ ″ O
454 ″ ″ ″ ″ ″ S
455 ″
Figure USRE037979-20030204-C00512
 		″ ″ ″ O
456 ″ ″ ″ ″ ″ S
457 ″
Figure USRE037979-20030204-C00513
 		″ ″ ″ O
458 ″ ″ ″ ″ ″ S
459 —C2H5
Figure USRE037979-20030204-C00514
Figure USRE037979-20030204-C00515
 		—H ″ S
460 ″
Figure USRE037979-20030204-C00516
 		″ ″ ″ O
461 ″ ″ ″ ″ ″ S
462 ″
Figure USRE037979-20030204-C00517
 		″ ″ ″ O
463 ″ ″ ″ ″ ″ S
464 ″
Figure USRE037979-20030204-C00518
 		″ ″ ″ O
465 ″ ″ ″ ″ ″ S
466 ″
Figure USRE037979-20030204-C00519
 		″ ″ ″ O
467 ″ ″ ″ ″ ″ S
468 ″
Figure USRE037979-20030204-C00520
 		″ ″ ″ O
469 ″ ″ ″ ″ ″ S
470 —C2H5
Figure USRE037979-20030204-C00521
Figure USRE037979-20030204-C00522
 		—H O O
471 ″ ″ ″ ″ ″ S
472 ″
Figure USRE037979-20030204-C00523
 		″ ″ ″ O 92.5˜95
473 ″ ″ ″ ″ ″ S
474 ″
Figure USRE037979-20030204-C00524
 		″ ″ ″ O 160˜ 160.7
475 ″ ″ ″ ″ ″ S
476 ″
Figure USRE037979-20030204-C00525
Figure USRE037979-20030204-C00526
 		″ ″ O
477 ″ ″ ″ ″ ″ S
478 ″
Figure USRE037979-20030204-C00527
 		″ ″ ″ O
479 ″ ″ ″ ″ ″ S
480 ″
Figure USRE037979-20030204-C00528
 		″ ″ ″ O
481 —C2H5
Figure USRE037979-20030204-C00529
Figure USRE037979-20030204-C00530
 		—H O S
482 ″
Figure USRE037979-20030204-C00531
Figure USRE037979-20030204-C00532
 		″ ″ ″
483 ″
Figure USRE037979-20030204-C00533
 		″ ″ ″ O
484 ″ ″ ″ ″ ″ S
485 —CH3
Figure USRE037979-20030204-C00534
Figure USRE037979-20030204-C00535
 		″ ″ O 118˜ 120
486 ″
Figure USRE037979-20030204-C00536
Figure USRE037979-20030204-C00537
 		″ ″ O
487 ″ ″ ″ ″ ″ S
488 —C2H5 ″ ″ ″ ″ O
489 ″ ″ ″ ″ ″ S
490 —CH3
Figure USRE037979-20030204-C00538
 		″ ″ ″ O
491 ″ ″ ″ ″ ″ S
492 —C2H5
Figure USRE037979-20030204-C00539
Figure USRE037979-20030204-C00540
 		—H O O
493 ″ ″ ″ ″ ″ S
494
Figure USRE037979-20030204-C00541
Figure USRE037979-20030204-C00542
Figure USRE037979-20030204-C00543
 		″ ″ O
495 ″ ″
Figure USRE037979-20030204-C00544
 		″ ″ ″
496 ″ ″
Figure USRE037979-20030204-C00545
 		″ ″ ″ 112˜ 114
497 ″ ″ ″ ″ ″ S 138˜ 140
498 ″
Figure USRE037979-20030204-C00546
 		″ ″ ″ O
499 ″ ″ ″ ″ ″ S
500 ″
Figure USRE037979-20030204-C00547
 		″ ″ ″ O
501
Figure USRE037979-20030204-C00548
 		″
Figure USRE037979-20030204-C00549
 		″ ″ S
502 ″
Figure USRE037979-20030204-C00550
 		″ ″ ″ O
503
Figure USRE037979-20030204-C00551
Figure USRE037979-20030204-C00552
Figure USRE037979-20030204-C00553
 		−H O S
504 ″
Figure USRE037979-20030204-C00554
 		″ ″ ″ O
505 ″ ″ ″ ″ ″ S
506 ″
Figure USRE037979-20030204-C00555
 		″ ″ ″ O
507 ″ ″ ″ ″ ″ S
508 ″
Figure USRE037979-20030204-C00556
 		″ ″ ″ O
509 ″ ″ ″ ″ ″ S
510 ″
Figure USRE037979-20030204-C00557
 		″ ″ ″ O
511 ″ ″ ″ ″ ″ S
512 ″
Figure USRE037979-20030204-C00558
Figure USRE037979-20030204-C00559
 		″ ″ O 138˜ 141
513 ″ ″ ″ ″ ″ S 165˜ 168
514
Figure USRE037979-20030204-C00560
Figure USRE037979-20030204-C00561
Figure USRE037979-20030204-C00562
 		—H O O
515 ″ ″ ″ ″ ″ S
516 ″
Figure USRE037979-20030204-C00563
 		″ ″ ″ O
517 ″ ″ ″ ″ ″ S
518 ″
Figure USRE037979-20030204-C00564
 		″ ″ ″ O
519 ″ ″ ″ ″ ″ S
520 ″
Figure USRE037979-20030204-C00565
 		″ ″ ″ O
521 ″ ″ ″ ″ ″ S
522 ″
Figure USRE037979-20030204-C00566
 		″ ″ ″ O
523 ″ ″ ″ ″ ″ S
524 ″
Figure USRE037979-20030204-C00567
 		″ ″ ″ O
525
Figure USRE037979-20030204-C00568
Figure USRE037979-20030204-C00569
Figure USRE037979-20030204-C00570
 		—H O S
526 ″
Figure USRE037979-20030204-C00571
Figure USRE037979-20030204-C00572
 		″ ″ O
527 ″ ″ ″ ″ ″ S
528 ″
Figure USRE037979-20030204-C00573
 		″ ″ ″ O
529 ″ ″ ″ ″ ″ S
530 ″
Figure USRE037979-20030204-C00574
 		″ ″ ″ O
531 ″ ″ ″ ″ ″ S
532 ″
Figure USRE037979-20030204-C00575
 		″ ″ ″ O
533 ″ ″ ″ ″ ″ S
534 ″
Figure USRE037979-20030204-C00576
 		″ ″ ″ O
535 ″ ″ ″ ″ ″ S
536
Figure USRE037979-20030204-C00577
Figure USRE037979-20030204-C00578
Figure USRE037979-20030204-C00579
 		—H O O
537 ″ ″ ″ ″ ″ S
538 ″
Figure USRE037979-20030204-C00580
 		″ ″ ″ O
539 ″ ″ ″ ″ ″ S
540 ″
Figure USRE037979-20030204-C00581
 		″ ″ ″ O
541 ″ ″ ″ ″ ″ S
542 ″
Figure USRE037979-20030204-C00582
Figure USRE037979-20030204-C00583
 		″ ″ O
543 ″ ″ ″ ″ ″ S
544 ″
Figure USRE037979-20030204-C00584
 		″ ″ ″ O
545 ″ ″ ″ ″ ″ S
546 ″
Figure USRE037979-20030204-C00585
 		″ ″ ″ O
547
Figure USRE037979-20030204-C00586
Figure USRE037979-20030204-C00587
Figure USRE037979-20030204-C00588
 		—H O S
548 ″
Figure USRE037979-20030204-C00589
 		″ ″ ″ O
549 ″ ″ ″ ″ ″ S
550 ″
Figure USRE037979-20030204-C00590
 		″ ″ ″ O
551 ″ ″ ″ ″ ″ S
552 ″
Figure USRE037979-20030204-C00591
 		″ ″ ″ O
553 ″ ″ ″ ″ ″ S
554 ″
Figure USRE037979-20030204-C00592
 		″ ″ ″ O
555 ″ ″ ″ ″ ″ S
556 ″
Figure USRE037979-20030204-C00593
Figure USRE037979-20030204-C00594
 		″ ″ O
557 ″ ″ ″ ″ ″ S
558
Figure USRE037979-20030204-C00595
Figure USRE037979-20030204-C00596
Figure USRE037979-20030204-C00597
 		—H O O
559 ″ ″ ″ ″ ″ S
560 ″
Figure USRE037979-20030204-C00598
 		″ ″ ″ O
561 ″ ″ ″ ″ ″ S
562 ″
Figure USRE037979-20030204-C00599
 		″ ″ ″ O
563 ″ ″ ″ ″ ″ S
564 ″
Figure USRE037979-20030204-C00600
 		″ ″ ″ O
565 ″ ″ ″ ″ ″ S
566 ″
Figure USRE037979-20030204-C00601
 		″ ″ ″ O
567 ″ ″ ″ ″ ″ S
568 ″
Figure USRE037979-20030204-C00602
 		″ ″ ″ O
569
Figure USRE037979-20030204-C00603
Figure USRE037979-20030204-C00604
Figure USRE037979-20030204-C00605
 		—H O S
570
Figure USRE037979-20030204-C00606
Figure USRE037979-20030204-C00607
Figure USRE037979-20030204-C00608
 		″ ″ O
571 ″
Figure USRE037979-20030204-C00609
 		″ ″ S
572 ″ ″
Figure USRE037979-20030204-C00610
 		″ ″ O
573 ″ ″ ″ ″ ″ S
574 ″
Figure USRE037979-20030204-C00611
Figure USRE037979-20030204-C00612
 		″ ″ O 94˜97
575 ″ ″ ″ ″ ″ S 123˜ 124
576 ″
Figure USRE037979-20030204-C00613
 		″ ″ ″ O
577 ″ ″ ″ ″ ″ S
578 ″
Figure USRE037979-20030204-C00614
 		″ ″ ″ O
579 ″ ″ ″ ″ ″ S
580
Figure USRE037979-20030204-C00615
Figure USRE037979-20030204-C00616
Figure USRE037979-20030204-C00617
 		—H O O
581 ″ ″ ″ ″ ″ S
582 ″
Figure USRE037979-20030204-C00618
 		″ ″ ″ O
583 ″ ″ ″ ″ ″ S
584 ″
Figure USRE037979-20030204-C00619
 		″ ″ ″ O
585 ″ ″ ″ ″ ″ S
586 ″
Figure USRE037979-20030204-C00620
 		″ ″ ″ O
587 ″ ″ ″ ″ ″ S
588 ″
Figure USRE037979-20030204-C00621
 		″ ″ ″ O
589 ″ ″ ″ ″ ″ S
590 ″
Figure USRE037979-20030204-C00622
Figure USRE037979-20030204-C00623
 		″ ″ O
591
Figure USRE037979-20030204-C00624
Figure USRE037979-20030204-C00625
Figure USRE037979-20030204-C00626
 		—H O S
592 ″
Figure USRE037979-20030204-C00627
 		″ ″ ″ O
593 ″ ″ ″ ″ ″ S
594 ″
Figure USRE037979-20030204-C00628
 		″ ″ ″ O
595 ″ ″ ″ ″ ″ S
596 ″
Figure USRE037979-20030204-C00629
 		″ ″ ″ O
597 ″ ″ ″ ″ ″ S
598 ″
Figure USRE037979-20030204-C00630
 		″ ″ ″ O
599 ″ ″ ″ ″ ″ S
600 ″
Figure USRE037979-20030204-C00631
 		″ ″ ″ O
601 ″ ″ ″ ″ ″ S
602
Figure USRE037979-20030204-C00632
Figure USRE037979-20030204-C00633
Figure USRE037979-20030204-C00634
 		—H O O
603 ″ ″ ″ ″ ″ S
604 ″
Figure USRE037979-20030204-C00635
Figure USRE037979-20030204-C00636
 		″ ″ O
605 ″ ″ ″ ″ ″ S
606 ″
Figure USRE037979-20030204-C00637
 		″ ″ ″ O
607 ″ ″ ″ ″ ″ S
608 ″
Figure USRE037979-20030204-C00638
 		″ ″ ″ O
609 ″ ″ ″ ″ ″ S
610 ″
Figure USRE037979-20030204-C00639
 		″ ″ ″ O
611 ″ ″ ″ ″ ″ S
612 ″
Figure USRE037979-20030204-C00640
 		″ ″ ″ O
613
Figure USRE037979-20030204-C00641
Figure USRE037979-20030204-C00642
Figure USRE037979-20030204-C00643
 		—H O S
614 ″
Figure USRE037979-20030204-C00644
 		″ ″ ″ O
615 ″ ″ ″ ″ ″ S
616 ″
Figure USRE037979-20030204-C00645
 		″ ″ ″ O
617 ″ ″ ″ ″ ″ S
618 ″
Figure USRE037979-20030204-C00646
Figure USRE037979-20030204-C00647
 		″ ″ O
619 ″ ″ ″ ″ ″ S
620 ″
Figure USRE037979-20030204-C00648
 		″ ″ ″ O
621 ″ ″ ″ ″ ″ S
622 ″
Figure USRE037979-20030204-C00649
 		″ ″ ″ O
623 ″ ″ ″ ″ ″ S
624
Figure USRE037979-20030204-C00650
Figure USRE037979-20030204-C00651
Figure USRE037979-20030204-C00652
 		—H O O
625 ″ ″ ″ ″ ″ S
626 ″
Figure USRE037979-20030204-C00653
 		″ ″ ″ O
627 ″ ″ ″ ″ ″ S
628 ″
Figure USRE037979-20030204-C00654
 		″ ″ ″ O
629 ″ ″ ″ ″ ″ S
630 ″
Figure USRE037979-20030204-C00655
 		″ ″ ″ O
631 ″ ″ ″ ″ ″ S
632 ″
Figure USRE037979-20030204-C00656
Figure USRE037979-20030204-C00657
 		″ ″ O
633 ″ ″ ″ ″ ″ S
634 ″
Figure USRE037979-20030204-C00658
 		″ ″ ″ O
635
Figure USRE037979-20030204-C00659
Figure USRE037979-20030204-C00660
Figure USRE037979-20030204-C00661
 		—H O S
636 ″
Figure USRE037979-20030204-C00662
 		″ ″ ″ O
637 ″ ″ ″ ″ ″ S
638 ″
Figure USRE037979-20030204-C00663
 		″ ″ ″ O
639 ″ ″ ″ ″ ″ S
640 ″
Figure USRE037979-20030204-C00664
 		″ ″ ″ O
641 ″ ″ ″ ″ ″ S
642 ″
Figure USRE037979-20030204-C00665
 		″ ″ ″ O
643 ″ ″ ″ ″ ″ S
644 ″
Figure USRE037979-20030204-C00666
 		″ ″ ″ O
645 ″ ″ ″ ″ ″ S
646 n-C3H7
Figure USRE037979-20030204-C00667
Figure USRE037979-20030204-C00668
 		—H O O
647 ″
Figure USRE037979-20030204-C00669
Figure USRE037979-20030204-C00670
 		″ ″ S
648 ″
Figure USRE037979-20030204-C00671
Figure USRE037979-20030204-C00672
 		″ ″ O
649 ″ ″ ″ ″ ″ S
650 ″
Figure USRE037979-20030204-C00673
 		″ ″ ″ O
651 ″ ″ ″ ″ ″ S
652 ″
Figure USRE037979-20030204-C00674
 		″ ″ ″ O
653 ″ ″ ″ ″ ″ S
654 ″
Figure USRE037979-20030204-C00675
 		″ ″ ″ O
655 ″ ″ ″ ″ ″ S
656 ″
Figure USRE037979-20030204-C00676
Figure USRE037979-20030204-C00677
 		″ ″ O
657 n-C3H7
Figure USRE037979-20030204-C00678
Figure USRE037979-20030204-C00679
 		—H O S
658 ″
Figure USRE037979-20030204-C00680
 		″ ″ ″ O
659 ″ ″ ″ ″ ″ S
660 ″
Figure USRE037979-20030204-C00681
 		″ ″ ″ O
661 ″ ″ ″ ″ ″ S
662 ″
Figure USRE037979-20030204-C00682
 		″ ″ ″ O
663 ″ ″ ″ ″ ″ S
664 —CH3
Figure USRE037979-20030204-C00683
Figure USRE037979-20030204-C00684
 		″ ″ S
665 ″
Figure USRE037979-20030204-C00685
 		″ ″ ″ O
666 ″ ″ ″ ″ ″ S
667 —CH2CH3
Figure USRE037979-20030204-C00686
 		″ ″ ″ O
668 —CH2CH3
Figure USRE037979-20030204-C00687
Figure USRE037979-20030204-C00688
 		—H O S
669
Figure USRE037979-20030204-C00689
Figure USRE037979-20030204-C00690
 		″ ″ ″ O
670 ″ ″ ″ ″ ″ S
671
Figure USRE037979-20030204-C00691
Figure USRE037979-20030204-C00692
 		″ ″ ″ O
672 ″ ″ ″ ″ ″ S
673 ″
Figure USRE037979-20030204-C00693
 		″ ″ ″ O
674 ″ ″ ″ ″ ″ S
675 —C2H5
Figure USRE037979-20030204-C00694
Figure USRE037979-20030204-C00695
 		″ ″ O 119˜ 121
676 ″ ″ ″ ″ ″ S 141˜ 142
677 ″
Figure USRE037979-20030204-C00696
 		″ ″ ″ O
678 ″ ″ ″ ″ ″ S
679 —C2H5
Figure USRE037979-20030204-C00697
Figure USRE037979-20030204-C00698
 		—H O O
680 ″ ″ ″ ″ ″ S
681
Figure USRE037979-20030204-C00699
Figure USRE037979-20030204-C00700
 		″ ″ ″ O
682 ″ ″ ″ ″ ″ S
683 ″
Figure USRE037979-20030204-C00701
 		″ ″ ″ O
684 ″ ″ ″ ″ ″ S
685 —C2H5
Figure USRE037979-20030204-C00702
Figure USRE037979-20030204-C00703
 		″ ″ O 167˜ 171
686 ″ ″ ″ ″ ″ S 139˜ 141
687
Figure USRE037979-20030204-C00704
Figure USRE037979-20030204-C00705
 		″ ″ ″ O
688 ″ ″ ″ ″ ″ S
689 —C2H5
Figure USRE037979-20030204-C00706
Figure USRE037979-20030204-C00707
 		″ ″ O 115˜ 116
690 —C2H5
Figure USRE037979-20030204-C00708
Figure USRE037979-20030204-C00709
 		—H O S 134˜ 135
691 ″
Figure USRE037979-20030204-C00710
 		″ ″ ″ O
692 ″ ″ ″ ″ ″ S
693 ″
Figure USRE037979-20030204-C00711
 		″ ″ ″ O
694 ″ ″ ″ ″ ″ S
695 ″
Figure USRE037979-20030204-C00712
 		″ ″ ″ O
696 ″ ″ ″ ″ ″ S
697
Figure USRE037979-20030204-C00713
Figure USRE037979-20030204-C00714
 		″ ″ ″ O
698 ″ ″ ″ ″ ″ S
699 —C2H5
Figure USRE037979-20030204-C00715
Figure USRE037979-20030204-C00716
 		″ ″ O
700 ″ ″ ″ ″ ″ S
701 —C2H5
Figure USRE037979-20030204-C00717
Figure USRE037979-20030204-C00718
 		—H O O
702 ″ ″ ″ ″ ″ S
703 ″
Figure USRE037979-20030204-C00719
Figure USRE037979-20030204-C00720
 		″ ″ O
704 ″ ″ ″ ″ ″ S 132˜ 134
705 ″
Figure USRE037979-20030204-C00721
 		″ ″ ″ O
706 ″ ″ ″ ″ ″ S
707 ″
Figure USRE037979-20030204-C00722
 		″ ″ ″ O
708 ″
Figure USRE037979-20030204-C00723
Figure USRE037979-20030204-C00724
 		″ ″ O
709 ″ ″ ″ ″ ″ S
710 ″
Figure USRE037979-20030204-C00725
 		″ ″ ″ O
711 ″ ″ ″ ″ ″ S
712 —C2H5
Figure USRE037979-20030204-C00726
Figure USRE037979-20030204-C00727
 		—H O O
713 ″ ″ ″ ″ ″ S
714 ″
Figure USRE037979-20030204-C00728
 		″ ″ ″ O
715 ″ ″ ″ ″ ″ S
716 ″
Figure USRE037979-20030204-C00729
Figure USRE037979-20030204-C00730
 		″ ″ O
717 ″ ″ ″ ″ ″ S
718 ″
Figure USRE037979-20030204-C00731
 		″ ″ ″ O
719 ″ ″ ″ ″ ″ S
720 ″
Figure USRE037979-20030204-C00732
 		″ ″ ″ O
721 ″ ″ ″ ″ ″ S
722 ″
Figure USRE037979-20030204-C00733
 		″ ″ ″ O
723 —C2H5
Figure USRE037979-20030204-C00734
Figure USRE037979-20030204-C00735
 		—H O S
724
Figure USRE037979-20030204-C00736
Figure USRE037979-20030204-C00737
Figure USRE037979-20030204-C00738
 		″ ″ O
725 ″ ″ ″ ″ ″ S
726 ″
Figure USRE037979-20030204-C00739
 		″ ″ ″ O
727 ″ ″ ″ ″ ″ S
728 ″
Figure USRE037979-20030204-C00740
 		″ ″ ″ O
729 ″ ″ ″ ″ ″ S
730
Figure USRE037979-20030204-C00741
Figure USRE037979-20030204-C00742
 		″ ″ ″ O
731 ″ ″ ″ ″ ″ S
732 ″
Figure USRE037979-20030204-C00743
Figure USRE037979-20030204-C00744
 		″ ″ O
733 ″ ″ ″ ″ ″ S
734
Figure USRE037979-20030204-C00745
Figure USRE037979-20030204-C00746
Figure USRE037979-20030204-C00747
 		—H O O
735 ″ ″ ″ ″ ″ S
736 ″
Figure USRE037979-20030204-C00748
 		″ ″ ″ O
737 ″ ″ ″ ″ ″ S
738 ″
Figure USRE037979-20030204-C00749
 		″ ″ ″ O
739 ″ ″ ″ ″ ″ S
740 ″
Figure USRE037979-20030204-C00750
Figure USRE037979-20030204-C00751
 		″ ″ O
741 ″ ″ ″ ″ ″ S
742 ″
Figure USRE037979-20030204-C00752
 		″ ″ ″ O
743 ″ ″ ″ ″ ″ S
744 ″
Figure USRE037979-20030204-C00753
 		″ ″ ″ O
745
Figure USRE037979-20030204-C00754
Figure USRE037979-20030204-C00755
Figure USRE037979-20030204-C00756
 		—H O S
746 ″
Figure USRE037979-20030204-C00757
 		″ ″ ″ O
747 ″ ″ ″ ″ ″ S
748 —C2H5
Figure USRE037979-20030204-C00758
Figure USRE037979-20030204-C00759
 		″ ″ O 108˜ 110
749 ″ ″ ″ ″ ″ S 136˜ 138
750 ″ ″
Figure USRE037979-20030204-C00760
 		″ ″ S
751 ″
Figure USRE037979-20030204-C00761
 		″ ″ ″ O
752 ″
Figure USRE037979-20030204-C00762
 		″ ″ ″ O
753 ″
Figure USRE037979-20030204-C00763
 		″ ″ ″ S
754
Figure USRE037979-20030204-C00764
Figure USRE037979-20030204-C00765
 		″ ″ ″ O
755 ″
Figure USRE037979-20030204-C00766
 		″ ″ ″ S
756
Figure USRE037979-20030204-C00767
Figure USRE037979-20030204-C00768
Figure USRE037979-20030204-C00769
 		—H O O
757 ″
Figure USRE037979-20030204-C00770
 		″ ″ ″ S
Figure USRE037979-20030204-C00771
Compound No. R1 R2 R3 Y Melting point (° C.)
758 —CH3
Figure USRE037979-20030204-C00772
Figure USRE037979-20030204-C00773
 		O
759 — — — S
760 —C2H5 — — O
761 — — — S
762 —CH3
Figure USRE037979-20030204-C00774
 		— O
763 — — — S
764 —C2H5 — — O
764 — — — S
766 —CH3
Figure USRE037979-20030204-C00775
 		— O
767 —CH3
Figure USRE037979-20030204-C00776
Figure USRE037979-20030204-C00777
 		S
768 —C2H5 — — O
769 — — — S
770
Figure USRE037979-20030204-C00778
Figure USRE037979-20030204-C00779
 		— O
771 — — — S
772 —
Figure USRE037979-20030204-C00780
 		— O
773 — — — S
774 —
Figure USRE037979-20030204-C00781
 		— O
775 — — — S
776 —
Figure USRE037979-20030204-C00782
 		— O
777 — — — S
778
Figure USRE037979-20030204-C00783
Figure USRE037979-20030204-C00784
Figure USRE037979-20030204-C00785
 		O
779 — — — S
780 —C2H5
Figure USRE037979-20030204-C00786
Figure USRE037979-20030204-C00787
 		O
781 — — — S
782 —
Figure USRE037979-20030204-C00788
 		— O
783 — — — S
784 —
Figure USRE037979-20030204-C00789
 		— O
785 — — — S
786 —
Figure USRE037979-20030204-C00790
 		— O
787 — — — S
788
Figure USRE037979-20030204-C00791
Figure USRE037979-20030204-C00792
 		— O
789
Figure USRE037979-20030204-C00793
Figure USRE037979-20030204-C00794
Figure USRE037979-20030204-C00795
 		S
790 —
Figure USRE037979-20030204-C00796
 		— O
791 — — — S
792 —
Figure USRE037979-20030204-C00797
 		— O
793 — — — S
794 —
Figure USRE037979-20030204-C00798
 		— O
795 — — — S
796
Figure USRE037979-20030204-C00799
Figure USRE037979-20030204-C00800
 		— O
797 — — — S
The compounds according to the invention of the formula I wherein R3 represents methyl or branched alkyl or —CH2—Z(CH2)n—R5 group where R5 represents a hydrogen, halogen atom, azido, alkoxy, aralkyloxy, optionally substituted aryl group or the like may be prepared in accordance with the following reaction formula (1), (2) or (3):
Figure USRE037979-20030204-C00801
wherein R1, R2, R3, R4, X and Y have the same meanings defined hereinbefore, X1 and X2 represent a halogen atom, arylthio, alkoxy group or the like, and M represents an alkaline metal.
Firstly, the compound of the formula II or IV is treated with an organic alkali metal compound in an ether solvent such as diethyl ether and tetrahydrofuran at a temperature of −80° to −10° C. for 0.2 to 10 hours.
Examples of the organic alkali metal compound include potassium bistrimethylsilylamide, sodium bistrimethylsilylamide and lithium alkylamide, and particularly preferred compounds among those are lithium diisopropylamide (LDA) and lithium 2,2,6,6-tetramethylpiperidide (LTMP). Such lithium alkylamides are preferably prepared immediately before the reaction. For example, lithium dialkylamide may be prepared by reacting a secondary amine such as diisopropylamine with an alkyl lithium such as n-butyl lithium in a solvent such as diethyl ether, dioxane, tetrahydrofuran and dimethoxyethane with stirring under the atmosphere of an inert gas such as argon at −80° C. to −10° C. for 0.2 to 5 hours.
The organic alkali metal compound is usually used in an amount of 1 to 5 moles per mole of the compound of the general formula II or IV.
Then, the electrophilic reagent of the general formula R2X1 or R1X2 is added to the reaction mixture in a ratio of about 1 to 5 moles to the compound of the general formula II or IV to allow the reaction under the same condition as in the reaction with the organic alkali metal compound.
The electrophilic reagent should have a group of R1 or R2 defined above, and examples of this reagent includes various diaryl disulfides, arylsulfenyl chlorides, dialkyl disulfides, dicycloalkyl disulfides, alkyl halides, aralkyl halides such as benzyl bromide, acid halides such as benzoyl halide and isobutyric halide, acid anhydrides and esters thereof, aryl-carbonylalkyl halides such as phenacyl chloride and the like.
The compounds of the general formula II can be prepared by a conventional method.
The compounds of the general formula IV can be prepared in accordance with the reaction formula (I) above (R1═H).
Figure USRE037979-20030204-C00802
wherein R1, R2, R3, R4, X and Y have the same meanings defined hereinbefore and X3 represents a halogen atom such as chlorine, bromine and iodine or sulfonyloxy group such as toluenesulfonyloxy and mesyloxy groups.
The compounds of the general formula VI are treated with an acid such as hydrochloric acid and bromic acid in a suitable solvent, for example, an alcohol such as methanol and ethanol and water at an appropriate temperature of from room temperature to 100° C. to obtain the compounds of the general formula VII.
Then, the compounds of the general formula VII are reacted with the compounds of the general formula VIII in a suitable solvent such as dimethylformamide, dimethyl sulfoxide, acetonitrile and tetrahydrofuran in the presence of a suitable base such as sodium hydride, sodium alkoxide, potassium alkoxide, potassium carbonate and sodium carbonate at a temperature of from ambient temperature to the boiling point of the solvent to obtain the compounds of the general formula I.
The starting compounds represented by the general formula VI can be prepared in accordance with the reaction formula (1) or (2).
When the objective compound has a hydroxyl group of R5 or when any intermediate compound of the reactions has a hydroxyl group, the reactions of (1) and (2) should be carried out using a starting compound or intermediate compound of which hydroxyl group is protected by an appropriate protective group instead of the unprotected compound of the formula II or IV or the like, and the protective group is then eliminated to obtain the target compound.
Any protective groups conventionally used for the protection of hydroxyl group may be used for this purpose so long as it is not eliminated under the alkaline condition.
Examples of such protective group are aralkyl groups such as benzyl, trityl, monomethoxytrityl, dimethoxytrityl and trimethoxytrityl, silyl groups such as trimethylsilyl, triethylsilyl, t-butyldimethylsilyl and t-butyldiphenylsilyl, tetrahydropyranyl group and substituted alkyl groups such as methoxymethyl group. Among those protective groups, silyl groups are particularly preferred.
The introduction of the protective group can be carried out by a conventional method.
For example, the introduction of the protective silyl group may be carried out by reacting the compound having the hydroxyl group with 1 to 10 times by mole of silylating reagent such as trimethylsilyl chloride and t-butyldimethylsilyl chloride at a temperature of from 0° to 50° C. in the presence of a base such as pyridine, picoline, diethylaniline, dimethylaniline, triethylamine and imidazole in a solvent such as dimethylformamide, acetonitrile, tetrahydrofuran and a mixture of those solvents in any combination.
The elimination of the protective group may be carried out by a conventional method corresponding to the kind of the protective group, for example, acid hydrolysis, ammonium fluoride treatment or catalytic reduction.
The compounds obtained by the reactions (1), (2) or (3) which have a nitro substituted phenylthio group at the 6-position may be converted into the compounds having an amino group by hydrogenation in accordance with the reaction formula (4) below. The hydrogenation can be carried out in an organic solvent such as alcohol and acetic acid in the presence of a catalyst such as palladium/carbon at an appropriate temperature of from room temperature to 80° C.:
Figure USRE037979-20030204-C00803
wherein the symbols have the same meanings as defined above.
The compounds having an arylthio, alkylthio or cycloalkylthio group can be converted to corresponding compounds having an arylsulfinyl, alkylsulfinyl or cycloalkylsulfinyl group by using an oxidizing agent such as hydrogen peroxide and m-chloroperbenzoic acid in accordance with the reaction formula (5) below:
Figure USRE037979-20030204-C00804
wherein R6 represents an aryl, alkyl or cycloalkyl group and the other symbols have the same meanings as defined above.
The compounds having phenyl sulfoxide group can be converted into corresponding compounds having a substituted arylthio or aryloxy group by reacting with sodium arylthiolate or sodium aryloxide having various substituents on the benzene ring in an organic solvent such as tetrahydrofuran, alcohol, dimethylformamide and acetonitrile at an appropriate temperature of from room temperature to 100° C. in accordance with the reaction formula (6) below:
Figure USRE037979-20030204-C00805
wherein A represents a sulfur or oxygen atom, R7 and R8 independently represent a halogen atom such as chlorine, bromine, fluorine and iodine, alkyl group such as methyl, ethyl, propyl and butyl, halogenated alkyl group such as trichloromethyl, alkoxy group such as methoxy, ethoxy, propoxy and butoxy, hydroxyl group, nitro group, amino group, cyano group and acyl group such as acetyl, and the other symbols have the same meanings as defined above.
The present compounds may be also prepared in accordance with, for example, the reaction formula (7) or (8) below:
Figure USRE037979-20030204-C00806
wherein R9 represents an alkyl group such as methyl and ethyl, aryl group such as phenyl and toluyl, a protective group such as silyl group or the like, and the other symbols have the same meanings as defined above.
The reactions of the formulae (7) and (8) can be carried out in an amine solvent such as diethylamine and triethylamine in the presence of a palladium catalyst at an appropriate temperature of from room temperature to 70° C. The reactions may be carried but more homogeneously by adding another solvent such as acetonitrile. As the catalyst, a palladium catalyst of bis(triphenylphosphine)palladium dichloride, tetrakis(triphenylphosphine)palladium(O) and bis(diphenylphosphino)ethanepalladium dichloride can be used in combination with cuprous iodide.
The present compounds can be prepared also in accordance with the reaction formula (9) or (10) below, and the reactions may be carried out in the same manner as the reactions of the formulae (7) and (8) except that an olefin derivative of H2C═CH—R10 wherein R10 represents an alkoxycarbonyl, nitrile, carbamoyl group and the like is used instead of the acetylene derivative in the reactions of the formulae (7) and (8):
Figure USRE037979-20030204-C00807
wherein the symbols have the same meanings as defined above.
The palladium catalyst may be the same as in the reaction of the formulae (7) and (8).
The compounds according to the invention can be prepared also in accordance with the reaction formula (11) below:
Figure USRE037979-20030204-C00808
wherein X4 represents a halogen atom such as chlorine, bromine and iodine, and the other symbols have the same meaning as defined above.
The compounds according to the invention can be prepared also in accordance with the reaction formula (12) or (13) below:
Figure USRE037979-20030204-C00809
Figure USRE037979-20030204-C00810
wherein the symbols have the same meanings as defined hereinbefore.
In the reactions of the formulae (12) and (13), intermediate compounds are prepared in accordance with the reaction formulae (1) and (2) as described hereinbefore except that a compound of OCH-CH(R11)(R12) wherein R11 and R12 independently represent a hydrogen atom, alkyl group such as methyl, ethyl and propyl or aryl group such as phenyl is used instead of the compounds R1X2 and R2X1, and then the intermediate compounds are dehydrated by a dehydrating agent such as mesyl chloride, tosyl chloride and thionyl chloride to produce the compounds according to the invention having an alkenyl group.
By hydrogenation, the alkynyl group of the compounds produced in the reactions of the formula (7) or (8) can be converted into the corresponding alkenyl or alkyl group and the alkenyl group of the compound produced in any one of the reactions formulae (9) to (13) can be converted into the corresponding alkyl group. For the reduction of alkynyl group into alkenyl group, the hydrogenation may be carried out at an appropriate temperature of from room temperature to 80° C. under hydrogen atmosphere in the presence of a catalyst such as palladium/barium sulfate, palladium/calcium carbonate, palladium/calcium carbonate/lead acetate and palladium/barium sulfate/quinoline in a solvent such as alcohol and acetic acid. For the reduction of alkenyl or alkynyl group into alkyl group, the hydrogenation may be carried out by using a catalyst such as palladium/carbon and palladium hydroxide under the same conditions as used for producing the alkenyl group.
The 6-benzyl substituted derivatives of the invention may be prepared in accordance with the reaction formula (14) below:
Figure USRE037979-20030204-C00811
wherein the symbols have the same meanings as defined hereinbefore
In the reactions of the formula (14), intermediate compounds are prepared in the same way as the reactions of the formula (1) using OHC-R13 where R13 represents an optionally substituted aryl group such as phenyl instead of R1X2 and the intermediate compounds are reduced by a suitable reducing agent to convert the hydroxyl group into a hydrogen atom. The reduction can be carried out by using hydrogen gas in the presence of palladium/carbon or palladium hydroxide.
The 6-substituted acyclouridine or acyclothymidine derivatives obtained in the above-described reactions can be converted into 4-thio derivatives by heating them with 2,4-bis(4-methoxyphenyl)-1,3-dithia-2,4-diphosphetane-2,4-disulfide in a solvent such as toluene and xylene in accordance with the reaction formula (15) below:
Figure USRE037979-20030204-C00812
wherein the symbols have the same meanings as defined hereinbefore.
The 4-thio derivatives can be also prepared by preparing corresponding 4-chloro derivatives by chlorination of corresponding uridine or thymidine derivatives by a chlorinating agent such as phosphorous pentachloride or phosphorous oxychloride and reacting the 4-chloro derivatives with sodium bisulfide.
Further, 4-amino derivatives can be prepared by reacting the acyclouridine or thymidine derivatives with 1-(2-mesitylenesulfonyl)-3-nitro-1,2,4-triazole in the presence of diphenylphosphoric acid in a solvent such as pyridine to produce corresponding 4-(3-vitro-1,2,4-triazole) derivatives which are converted to the corresponding 4-amino derivatives by aqueous ammonia at an appropriate temperature of from room temperature to 100° C. in accordance with the reaction formula (16) below:
Figure USRE037979-20030204-C00813
wherein the symbols have the same meanings as define hereinbefore.
Thus, the compounds of the invention represented by the formula I′ are prepared as described above.
The above-obtained compounds where R4 is a hydrogen atom may be converted into corresponding compounds having R4 other than the hydrogen atom in accordance with the reaction formula (17) below:
Figure USRE037979-20030204-C00814
wherein X5 represents a halogen atom such as chlorine, bromine and iodine or sulfonyloxy group such as toluenesulfonyloxy and mesyloxy, and the other symbols have the same meanings as defined hereinbefore.
The reaction of the formula (17) may be carried out in a suitable solvent such as tetrahydrofuran, acetonitrile, dimethylformamide, pyridine and alcohol in the presence of a base in an amount of 1 to 2 times of the starting compound at a suitable temperature from room temperature to the boiling point of the solvent. Examples of the base include sodium alkoxide, potassium alkoxide, potassium carbonate, sodium carbonate, sodium hydride and the like.
The compounds of the invention where R5 is a hydroxy group, which are obtained in any of the reactions of formula (1) to (17), may be converted into corresponding compounds having a substituted hydroxyl group in accordance with any of the reaction formulae (18) to (21) below:
Figure USRE037979-20030204-C00815
wherein R14 represents an optionally branched alkyl group, optionally substituted aryl grow or heterocyclic group, X6 represents a halogen atom such as chlorine, bromine and iodine or —OCOR14, and the other symbols have the same meanings as defined hereinbefore.
The reaction of the formula (18) may be carried out in a suitable solvent such as tetrahydrofuran, acetonitrile, dimethylformamide, pyridine, dichloromethane and chloroform in the presence of a base in an amount of 1 to 2 times of the starting compound at a suitable temperature from room temperature to the boiling point of the solvent. Examples of the base include triethylamine, pyridine, imidazole, sodium carbonate, potassium carbonate, sodium hydroxide and the like.
Figure USRE037979-20030204-C00816
wherein R15 represents an optionally branched alkyl group or aralkyl group, X7 represents a halogen atom such as chlorine, bromine and iodine or —OCOOR15, and the other symbols have the same meanings as defined hereinbefore.
The reaction of the formula (19) may be carried out in a suitable solvent such as tetrahydrofuran, acetonitrile, dimethylformamide, pyridine, dichloromethane and chloroform in the presence of a base in as amount of 1 to 2 times of the starting compound at a suitable temperature from room temperature to the boiling paint of the solvent. Examples of the base include triethylamine, pyridine, imidazole, sodium carbonate, potassium carbonate, sodium hydroxide and the
Figure USRE037979-20030204-C00817
wherein R16 represents an optionally branched alkyl group or aralkyl group, X8 represents a halogen atom such as chlorine, bromine and iodine or sulfonyloxy group such as toluenesulfonyloxy and mesyloxy, and the other symbols have the same meanings as defined hereinbefore.
The reaction of the formula (20) may be carried out in a suitable solvent such as tetrahydrofuran, acetonitrile, dimethylformamide, pyridine, dichloromethane and chloroform in the presence of a base in an amount of 1 to 2 times of the starting compound at a suitable temperature from room temperature to the boiling point of the solvent. Examples of the base include triethylamine, pyridine, imidazole, sodium carbonate, potassium carbonate, sodium hydroxide and the like.
Figure USRE037979-20030204-C00818
wherein R17 represents an optionally branched alkyl group or aryl group, X9 represents an oxygen or sulfur atom, and the other symbols have the same meanings as defined hereinbefore.
The reaction of formula (21) may be carried out in an appropriate solvent such as tetrahydrofuran, acetonitrile, dimethylformamide, pyridine, dichloromethane and chloroform at an appropriate temperature of from room temperature to the boiling point of the solvent.
The compounds of the present invention obtained as described hereinbefore and represented by the formula I or I′ may be separated and purified by any of the conventional methods for the separation and purification of nucleosides, for example, recrystallization, adsorption chromatography, ion exchange chromatography and the like.
The compound of the invention represented by the formula I or I′ may be converted into a pharmaceutically acceptable salt thereof by a conventional method. Such salt may be, for example, an alkali metal salt such as sodium or potassium salt, alkaline earth salt such as magnesium salt, ammonium salt or alkylammonium salt such as methylammonium, dimethylammonium, trimethylammonium, tetramethylammonium salt or the like.
The compounds according to invention can be administered to human beings via any route, oral, rectal, parenteral or local for the prevention or treatment of the infection of viruses such as retrovirus. The administration dose of the compounds according to the invention may be determined according to age, physical condition, body weight and the like of a patient to be treated; however, a suitable daily does of the compounds is 1 to 100 mg/(body weight)kg, preferably 5 to 50 mg/(body weight)kg and it is administered in one to several times.
The compound of the invents is generally prepared in a pharmaceutical composition with a suitable carrier, excipient and other additives. Either a liquid carrier or solid carrier may be suitably used for the present antiviral agent.
Examples of the solid carrier are lactose, kaolin, sucrose, crystalline cellulose, corn starch, talc, agar, pectin, stearic acid, magnesium stearate, lecithin, sodium chloride and the like.
Examples of the liquid are glycerin, peanut oil, polyvinyl pyrrolidone, olive oil, ethanol, benzyl alcohol, propylene glycol, water and the like.
The present antiviral agent may be made in various forms. For example, it may be in the form of a tablet, powder, granule, capsule; suppository, troche or the like when a solid carrier is used, and it may be also in the form of syrup, emulsion, soft gelatin capsule, cream, gel, paste, spray, injection solution, or the like when a liquid carrier is used.
The novel 6-substituted ayclopyrimidine nucleoside derivatives according to the sent invention have an effective antiviral activity against viruses such as retrovirus and have a relatively low toxicity against the host cell, hence the derivatives of the invention are extremely useful as an active ingredient of antiviral agent.
EXAMPLE
The present invention will be further illustrated hereinafter by way of examples, but these examples do not limit the invention and many variations and modifications can be made without departing from the scope of the present invention.
The numbers of the compounds used in the description of the examples correspond to those used in Table 1.
The starting compounds used in the examples such as
1-[(2-hydroxyethoxy)methyl]-6-phenylthio-2-thiothymine,
1-[(2-hydroxyethoxy)methyl]-6-phenylthiothymine,
1-[(2-hydroxyethoxy)methyl]-6-(m,m′-dimethylphenylthio)-2-thymine,
1-[(2-hydroxyethoxy)methyl]-6-(m,m′-dimethylphenylthio)-2-thiothymine,
1-[(2-hydroxyethoxy)methyl]-6-(m,m′-dichlorophenylthio)-thymine,
1-[(2-hydroxyethoxy)methyl]-6-benzylthymine,
1-[(2-hydroxyethoxy)methyl]-6-cyclohexylthiothymine,
1-[(2-hydroxyethoxy)methyl]-6-m-tolylthiothymine and the like were produced according to the methods described in the examples of PCT International Application WO89/09213.
EXAMPLE 1
Preparation of 1-[(2-acetoxyethoxy)methyl]-6-phenylthio-2-thiothymine (compound No. 1)
To 2 ml of pyridine, 0.31 g (1.0 mmole) of 1-[(2-hydroxyethoxy)methyl]-6-phenylthio-2-thiothymine and 0.10 ml (1.1 mmol of acetic anhydride were added under a flow of nitrogen, allowed to react for 2 hours at room temperature, concentrated to dryness under reduced pressure and crystallized from ethanol/water to obtain 0.62 g of the target compound (Yield: 88%).
EXAMPLES 2-6
Using the following compounds in place of 1-[(2-hydroxyethoxy)methyl]-6-phenylthio-2-thiothymine in Example 1, Compounds Nos.2 to 6 in Table 1 were obtained in the same manner as Example 1:
1-[(2-hydroxyethoxy)methyl]-6-phenylthiothymine,
1-[(2-hydroxyethoxy)methyl]-6-(m,m′-dimethylphenylthio)thymine,
1-[(2-hydroxyethoxy)methyl]-6-(m,m′-dimethylphenylthio)-2-thiothymine,
1-[(2-hydroxyethoxy)methyl]-6-(m,m′-dichlorophenylthio)thymine, and
1-[(2-hydroxyethoxy)methyl]-6-benzylthymine.
EXAMPLES 7-13
Compounds Nos.7 to 13 in Table 1 were prepared in the same manner as Example 2 by using ethyl formats, i-butyryl chloride, pivaloyl chloride, decanoyl chloride, cyclohexanecarbonyl chloride, benzoyl chloride or nicotinyl chloride respectively in place of acetic anhydride in Example 2.
EXAMPLE 14
Compound No. 14 was prepared in the same manner as Example 2 by using t-butoxycarbonyl chloride in place of acetic anhydride in Example 2.
EXAMPLE 15
Compound No. 15 was obtained in the same manner as Example 2 by using 1-[(2-hydroxyethoxy) methyl]-6-cyclohexylthiothymine and benzyloxycarbonyl chloride in place of 1-[(2-hydroxyethoxy)methyl]-6-phenylthiothymine and acetic anhydride in Example 2 respectively.
EXAMPLE 16
Preparation of 1-[(2-phenylcarbamoyloxyethoxy) methyl]-6-m-tolylthiothymine (Compound No. 16)
To 2 ml of pyridine, 0.32 g (1.0 mmole) of 1-[(2-hydroxyethoxy)methyl]-6-m-tolylthiothymine and 0.12 ml (1.1 mmole) of phenyl isocyanate were added under a flow of nitrogen allowed to react for 18 hours at room temperature. The reaction mixture was concentrated to dryness under reduced pressure and crystallized from acetone/water to obtain 0.24 g of the target compound (Yield: 54%).
EXAMPLE 17 and 18
Compounds Nos.17 and 18 were prepared in the same manner as Example 16 by using ethyl isocyanate or phenyl thioisocyanate respectively in place of phenyl isocyanate.
EXAMPLE 19
Preparation of 1-[(2-benzyloxyethoxy)methyl]-6-phenylthiothymine (Compound No. 19)
To 4 ml of tetrahydrofuran, 0.17 g (4.2 mmol) of sodium hydride was added under a nitrogen flow, and stirred to form a suspension. To this suspension, a solution of 0.62 g (2.0 mmole) of 1-[(2-hydroxyethoxy)methyl]-6-phenylthiothymine in 2 ml of tetrahydrofuran was added slowly to react for 45 minutes at room temperature. The resultant was added with 0.24 ml (2.0 mmol) of benzyl bromide and 7.4 g (20 μmol) of tetrabutylammonium iodide and allowed to react for 15 hours. The reaction mixture was neutralized with acetic acid and distributed between chloroform and saturated aqueous solution of sodium by hydrogencarbonate, and the chloroform layer was concentrated to dryness under reduced pressure. The residue was dissolved in a small amount of chloroform, adsorbed on a silica gel column and eluted with 1% methanol/chloroform. The eluate was concentrated and crystallized from diethyl ether/hexane to obtain 0.64 g of the target compound (Yield: 80%).
EXAMPLES 20-21
Compounds Nos.20 and 21 were prepared in the same manner as Example 19 by using methyl bromide or bromopentane respectively in place of benzyl bromide.
EXAMPLE 22
Preparation of 1-(methoxymethyl)-6-phenylthiothymine (Compound No. 22)
To 250 ml of methylene chloride, 25 g (0.20 mol) of thymine and 109 ml (0.44 mol) of bistrimethylsilylacetamide were added under a nitrogen flow, and stirred for 2.5 hours at room temperature. To this mixture, 24 g (0.30 mole) of chloromethyl methyl ether and 0.59 g (1.6 mmol) of tetrabutylammonium iodide were added and heated under reflux for 1.5 hours. Then, the reaction mixture was added with 400 ml of methanol and 100 ml of water slowly and concentrated under reduced pressure. The residue was crystallized from ethyl acetate to obtain 1-(methoxymethyl)-thymine. Then, 119 ml of lithium diisopropylamide (0.25 mol) solution in tetrahydrofuran (2.1M) was added to 335 ml of tetrahydrofuran under a nitrogen flow at −70° C., to which a suspension of 17.0 g (0.10 mol) 1-(methoxymethyl)thymine in 107 ml of tetrahydrofuran added dropwise over 30 minutes. After stirring for 2.5 hours at −70° C., the reaction mixture was with a solution of 43.6 g of diphenyl disulfide in 49 ml of tetrahydrofuran dropwise over 20 minutes and allowed to react for 20 minutes. The reaction mixture was added with 35 ml of acetic acid, brought to room temperature and then added with 1 l of ethyl acetate. The mixture was washed with water (100 ml×5) and saturated solution of sodium hydrogencarbonate (twice), dried on magnesium sulfate and concentrated under reduced pressure. The residue was crystallized from ethanol to obtain 20 g of the target compound (Yield: 73%).
EXAMPLES 23-26
Compounds Nos.23 to 26 were prepared in the same manner as Example 22 by using 1-(ethoxymethyl)thymine, 1-[(2-azidoethoxy) methyl]thymine, 1-[(2-fluoroethoxy)methyl]thymine or 1-[(2-chloroethoxy)methyl]thymine respectively in place of 1-(methoxymethyl)thymine.
EXAMPLE 27
Preparation of 6-phenylthiothymine (Compound No. 27)
To 100 ml of concentrated hydrochloric acid, 17.2 g (62 mmole) of 1-(methoxymethyl)-6-phenylthiothymine was added and allowed to react for 2 hours at 80° C. The reaction mixture was concentrated under reduced pressure and crystallized from ethanol to obtain 3.8 g of the target compound (Yield: 26%).
EXAMPLE 28
Preparation of 1-methyl-6-phenylthiothymine (Compound No. 28)
To 1 ml of dimethyl sulfoxide, 20 mg (85 μmol) of 6-phenylthiothymine, 2.5 μl (40 μmol) of methyl iodide and 12 mg (85 μmol) of potassium carbonate were added and allowed to react for 6 hours at 80° C. The reaction mixture was concentrated under reduced pressure and adsorbed on a silica gel column and eluted with 1% methanol/chloroform. The eluate was concentrated and crystallized from diisopropyl ether to obtain 5.0 mg of the target compound (Yield: 51%).
EXAMPLES 29-30
Compounds Nos.29 and 30 were prepared in the same manner as Example 28 by using ethyl tosylate or n-butyl iodide respectively in place of methyl iodide.
EXAMPLE 31
Preparation of 1-(4-hydroxybutyl) -6-phenylthiothymine (Compound No. 31)
To 2 ml of dimethyl sulfoxide, 468 mg (2.0 mmol) of 6-phenythiothymine, 358 mg (1.0 mmol) of 4-(t-butyldimethylsiloxy)-butyl-p-toluenesulphonate and 276 mg (2.0 mmol) of potassium carbonate were added and heated to react for 4 hours at 80° C. The reaction mixture was concentrated under reduced pressure, added with methanol and filtered. The filtrate was concentrated under reduced pressure, added with 20 ml of tetrahydrofuran and 1 ml of 1N hydrochloric acid and stirred for 90 minutes. The reaction mixture was concentrated under reduced pressure and adsorbed on a silica gel column and eluted with 2% methanol/chloroform The eluate was concentrated and crystallized from acetone/hexane to obtain 12.0 mg of the target compound (Yield: 4%).
EXAMPLE 32
Preparation of 1-(methylthiomethyl)-6-phenylthiothymine (Compound No. 32)
To 4 ml of dimethylformamide, 0.17 ml (2.0 mmol) of chloromethylmethylsulfide, 0.47 g (2.0 mmol) of 6-phenylthiothymine, 0.56 ml (2.0 mmol) of triethylamine were added and allowed to react for 22 hours at room temperature. The reaction mixture was concentrated under reduced pressure and the residue was adsorbed on a silica gel column and eluted with chloroform. The eluate was concentrated and crystallized from ethyl acetate to obtain 45 mg of the target compound (Yield: 8%).
EXAMPLE 33
Preparation of 1-[(2-hydroxyethoxy)methyl]-3-benzyl-6-phenylthiothymine (Compound No. 33)
To 2 ml of dimethylformamide 0.62 g (2.0 mmol) of 1-[(2-hydroxyethoxy)methyl]-6-penylthiothymine, 0.26 ml (2.2 mmol) of benzyl bromide and 0.38 ml (2.2 mmol) of ethyldiisopropylamine were added and allowed to react for 5 days at room temperature under nitrogen atmosphere. The reaction mixture was concentrated under reduced pressure and the residue was adsorbed on a silica gel column and eluted with 1% methano/chloroform to obtain 0.24 g of the target compound (Yield: 30%).
EXAMPLE 34
Compounds No. 34 was prepared in the same manner as Example 33 by using methyl iodide in place of benzyl bromide.
EXAMPLE 35
Preparation of 1-ethoxymethyl-5-ethyl-6-phenylthiouracil (Compound No. 247)
To 100 ml of methylene chloride 5.1 g (40 mmol) of 5-ethyluracil and 22 ml (0.88 mmol) of bistrimethylsilylacetamide were added under a nitrogen atmosphere and stirred for 40 minutes at room temperature. To this mixture, 4.1 ml (88 mmole) of chloromethyl yl ether and 0.15 g (0.4 mmol) of tetrabutylammonium iodide were added and heated under reflux for 15 hours. Then, the reaction mixture was poured carefully into 50 ml of saturated aqueous solution of sodium hydrogencarbonate and filtered through Celite. The organic layer was washed with water, dried on magnesium sulfate and concentrated under reduced pressure. The residue was crystallized from ethyl acetate to obtain 6.4 g of (ethoxymethyl) 5-ethyluracil (Yield: 81%).
Then, 2.2 ml of lithium diisopropylamide (4.4 mmol) solution in tetrahydrofuran (2.1M) was added to 6 ml of tetrahydrofuran under a nitrogen atmosphere at −70° C., to which a solution of 0.40 g (2.0 mmol) of 1-ethoxymethyl-5-ethyluracil in 3 ml of tetrahydrofuran was added dropwise over 15 minute. After stirring for 1 hour at −70° C., the reaction mixture was added with a solution of 0.57 g of diphenyl disulfide in 2 ml of tetrahydrofuran dropwise over 10 minutes and allowed to react for 30 minutes. The reaction mixture was added with 1 ml of acetic acid, brought to room temperature and then added with 30 ml of ethyl acetate. The mixture was washed with water (3 mix 5) and saturated aqueous solution of sodium hydrogencarbonate (twice), dried on magnesium sulfate and′ concentrated under reduced pressure. The residue was purified by silica gel chromatography (ethyl acetate/hexane=3:17) and crystallized from ethyl acetate to obtain 0.61 g of 1-ethoxymethyl-5-ethyl-6-phenylthiouracil (Yield: 32%).
EXAMPLE 36
Compound No. 357 was obtained in the same way as Example 35 by using 3,3′,5,5′-tetramethylphenyl disulfide in place of diphenyl disulfide.
EXAMPLE 37
Preparation of 1-ethoxymethyl-5-ethyl-6-phenylthio-2-thiouracil (Compound No. 358)
To 100 ml of methylene chloride, 5.1 g (40 mmol) of 2-thiouracil and 22 ml (88 mmol) of bistrimethylsilylacetamide were added under a nitrogen atmosphere, and stirred for 40 minutes at room temperature. To this mixture, 8.2 ml
(88 mmole) of chloromethyl ethyl ether and 0.15 g (0.4 mmol) of tetrabutylammonium iodide were added and heated under reflux for 15 hours. Then, the reaction mixture was poured carefully into 50 ml of saturated aqueous solution of sodium hydrogencarbonate and filtered through Celite. The organic layer was washed with water, dried on magnesium sulfate and concentrated under reduced pressure. The residue was crystallized from ethyl acetate to obtain 1.1 g of 1-ethoxymethyl-2-thiouracil (Yield: 15%).
Then, 3.3 ml lithium diisopropylamide solution in tetrahydrofuran (2.1M) was added to 9 ml of tetrahydrofuran under a nitrogen atmosphere at −70° C., to which a solution of 0.56 g (3.0 mmol) of 1-ethoxymethyl-2-thiouracil in 3 ml of tetrahydrofuran was added dropwise over 15 minutes. After stirring for 1 hour at −70° C., the reaction mixture was added with a solution of 0.85 g (3.9 mmol) of diphenyl disulfide in 1 ml of tetrahydrofuran dropwise over 10 minutes and allowed to react for 20 minutes. The reaction mixture was added with 1 ml of acetic acid, brought to room temperature and then added with 30 ml of ethyl acetate. The mixture was washed with water (3 ml×5) and saturated aqueous solution of sodium hydrogencarbonate (twice), dried on magnesium sulfate and concentrated under reduced pressure. The residue was purified by silica gel chromatography (ethyl acetate/hexane=3:17), crystallized from ethyl acetate to obtain 0.64 g of 1-ethoxymethyl-6-phenylthio-2-thiouracil (Yield: 73%).
Then, 2.1 ml of 1.6M butyl lithium (3.4 mmol) solution in hexane was added to a solution of 0.57 ml (3.4 mmol) 2,2,6,6-tetramethylpyperidine in 8 ml of tetrahydrofuran under a nitrogen atmosphere at −70° C., warmed to −50° C., and stirred for 20 minutes. After cooling to −70° C. again, the mixture was added with a solution of 0.44 g (1.5 mmol) of 1-ethoxymethy-6-phenylthio-2-thiouracil in 4 ml tetrahydrofuran dropwise over 15 minutes, stirred for an hour, added with 1.2 ml (15 mmol) ethyl iodide and stirred for 19 hours. Then, the mixture was added with 1 ml acetic acid, brought to room temperature, added with 30 ml ethyl acetate, washed with water and saturated aqueous solution of sodium chloride, dried on magnesium sulfate and concentrated under reused pressure. The residue was purified by silica gel chromatography (ethyl acetate/hexane=3:17) and crystallized from ethyl acetate to obtain 96 mg of the title compound (Yield: 20%).
EXAMPLE 38
Compound No. 359 was prepared in the same way as Example 37 by using 3,3′,5,5′-tetramethyldiphenyl disulfide in place of diphenyl disulfide.
EXAMPLE 39
Compound No. 360 was prepared in the same way as Example 35 by using benzyl chloromethyl ether in place of chloromethyl ethyl ether.
EXAMPLE 40
Compound No. 361 was prepared in the same way as Example 35 by using benzyl chloromethyl ether and 3,3′,5,5′-tetramethyldiphenyl disulfide respectively in place of chloromethyl ethyl ether and diphenyl disulfide.
EXAMPLE 41
Compound No 362 was prepared in the same way as Example 35 by using thymine and benzyl chloromethyl ether in place of 5-ethyluracil and chloromethyl ethyl ether.
EXAMPLE 42
Compound No. 41 was prepared in the same way as Example 22 by using chloromethyl propyl ether in place of chloromethyl methyl ether.
EXAMPLE 43
Compound No. 485 was prepared in the same way as Example 22 by using butyl chloromethyl ether in place of chloromethyl methyl ether.
EXAMPLE 44
Compound No. 365 was prepared in the same way as Example 35 by using 3,3′,5,5′-tetrachlorodiphenyl disulfide in place of diphenyl disulfide.
EXAMPLE 45
Compound No. 366 was prepared in the same way as Example 35 by using 5-ethyl-2-thiouracil and 3,3′,5,5′-tetrachlorodiphenyl disulfide respectively in place of 5-ethyluracil and diphenyl disulfide.
EXAMPLE 46
Compound No. 496 was prepared in the same way as Example 35 by using 5-isopropyluracil in place of 5-ethyluracil.
EXAMPLE 47
Compound No. 497 was prepared in the same way as Example 35 by using 5-isopropyl-2-thiouracil in place of 5-ethyluracil.
EXAMPLE 48
Compound No. 574 was prepared in the same way as Example 35 by using 5-cyclopropyluracil in place of 5-ethyluracil.
EXAMPLE 49
Compound No. 575 was prepared in the same way as Example 35 by using 5-cyclopropyl-2-thiouracil in place of 5-ethyluracil.
EXAMPLE 50
Compound No. 675 was prepared in the same way as Example 35 by using chloromethyl isopropyl other in place of chloromethyl ethyl ether.
EXAMPLE 51
Compound No. 675 was prepared in the same way as Example 35 by using 5-ethyl-2-thiouracil and chloromethyl isopropyl ether respectively in place of 5-ethyluracil and chloromethyl ethyl ether.
EXAMPLE 52
Compound No. 685 was prepared in the same way as Example 35 by using chloromethyl cyclohexyl ether in place of chloromethyl ethyl ether.
EXAMPLE 53
Compound No. 686 was prepared in the same way as Example 35 by using 5-ethyl-2-thiouracil and chloromethyl cyclohexyl ether respectively in place of 5-ethyluracil and chloromethyl ethyl ether.
EXAMPLE 54
Compound No. 689 was prepared in the same way as Example 35 by using chloromethyl cyclohexylmethyl ether in place of chloromethyl ethyl ether.
EXAMPLE 55
Compound No. 690 was prepared in the same way as Example 35 by using 5-ethyl-2-thiouracil and chloromethyl cyclohexylmethyl ether respectively in place of 5-ethyluracil and chloromethyl ethyl ether.
EXAMPLE 56
Compound No. 512 was prepared in the same way as Example 35 by using 5-isopropyluracil and benzyl chloromethyl ether respectively in place of 5-ethyluracil and chloromethyl ethyl ether.
EXAMPLE 57
Compound No. 513 was prepared in the same way as Example 35 by using 5-isopropyl-2-thiouracil and benzyl chloromethyl ether respectively in place of 5-ethyluracil and chloromethyl ethyl ether.
EXAMPLE 58
Compound No. 748 was prepared in the same way as Example 35 by using chloromethyl phenetyl ether in place of chloromethyl ethyl ether.
EXAMPLE 59
Compound No. 749 was prepared in the same way as Example 35 by using 5-ethyl-2-thioracil and chloromethyl phenetyl ether respectively in place of 5-ethyluracil and chloromethyl ethyl ether.
EXAMPLE 60
Compound No. 372 was prepared in the same way as Example 35 by using 5-ethyl-2-thiouracil and chloromethyl 4-methylbenzyl ether respectively in place of 5-ethyluracil and chloromethyl ethyl ether.
EXAMPLE 61
Compound No. 704 was prepared in the same way as Example 35 by using 5-ethyl-2-thiouracil and 4-chlorobenzyl chloromethyl ether respectively in place of 5-ethyluracil and chloromethyl ethyl ether.
EXAMPLE 62
Preparation of 6-benzyl-1-ethoxymethyl-5-ethyluracil (Compound No. 472)
To 100 ml of methylene chloride, 5.1 g (40 mmol) of 5-ethyluracil and 22 ml (88 mmol) of bistrimethylsilylacetamide were added under a nitrogen atmosphere and stirred for 40 minutes at room temperature. To this mixture, 4.1 ml (88 mmole) of chloromethyl ethyl ether and 0.15 g (0.4 mmol) of tetrabutylammonium iodide were added and heated under reflux for 15 hours. Then, the reaction mixture was poured into 50 ml of saturated sodium bicarbonate solution carefully and filtered through Celite. The organic layer was washed with water, dried on magnesium sulfate and concentrated under reduced pressure. The residue was crystallized from ethyl acetate to obtain 6.4 g of 1-ethoxymethyl-5-ethyluracil (Yield: 81%).
Then, 2.2 ml (4.4 mmol) of lithium diisopropylamide solution in tetrahydrofuran (2.1M) was added to 6 ml of tetrahydrofuran under a nitrogen atmosphere at −70° C., to which a solution of 0.40 g (2.0 mmol) of 1-ethoxymethyl-5-ethyluracil in 3 ml of tetrahydrofuran was added dropwise over 15 minutes. After stirring for 1 hour at −70° C., the reaction mixture was added with a solution of 0.27 g (2.6 mmol) of benzaldehyde in 2 ml of tetrahydrofuran dropwise over 10 minutes and allowed to react for 30 minutes. The reaction mixture was added with 1 ml of acetic acid, brought to room temperature and then added with 30 ml of ethyl acetate. The mixture was washed with water (3 ml ×5) and saturated aqueous solution of sodium hydrogencarbonate (twice), dried on magnesium sulfate and concentrated under reduced pressure.
The residue was dissolved in 10 ml of ethanol, added with 20 mg of 20% palladium hydroxide/carbon and stirred under a hydrogen atmosphere for a day at 55° C. Then, after removing the catalyst by filtration, the reaction mixture was concentrated. The residue was crystallized from hexane to obtain 0.28 g of 6 -benzyl-1-ethoxymethyl-5-ethyluracil (Yield: 85%).
EXAMPLE 63
Compound No. 474 was prepared in the same way as Example 62 by using 3,5-dimethylbenzaldehyde in place of benzaldehyde.
EXAMPLE 64
Preparation of 1-butyl-5-ethyl-6-phenylthiouracil (compound No. 252)
To a solution of 5.6 g (40 mmol) of 5-ethyluracil in 60 ml of dimethylformamide, 5.5 g (40 mmol) of potassium carbonate and 2.3 ml (20 mmol) of n-iodobutane were added and stirred for 2 hours at 120° C. The reaction mixture was concentrated under reduced pressure and distributed between dichloromethane and aqueous solution of ammonium chloride, and the organic layer was concentrated under reduced pressure. The residue was adsorbed on a silica gel column and eluted with 30% ethyl acetate/hexane to obtain 2.7 g of 1-butyl-5-ethyluracil (Yield: 69%).
Then, a solution of 4.4 mmol of lithium diisopropylamide in 2.8 ml of tetrahydrofuran was added dropwise to a solution of 392 mg (2.0 mmol) 1-butyl-5-ethyluracil in 9 ml of tetrahydrofuran under a nitrogen atmosphere at −70° C. and stirred for 70 minutes at −70° C. and further 5 minutes at −25° C. The mixture was cooled to −70° C. again, added with a solution of 567 mg (2.6 mmol) diphenyl disulfide in 3 ml of tetrahydrofuran, stirred for 20 minutes, added with 1 ml of acetic acid, brought to room temperature, washed with saturated aqueous solution of sodium chloride and concentrated under reduced pressure. The residue was adsorbed on a silica gel, eluted with 10% ethyl acetate/hexane and crystallized from hexane to obtain 40 mg of 1-butyl-5-ethyl-6-phenylthiouracil (Yield: 7%).
EXAMPLE 65
Compound No. 363 was prepared in the same way as Example 35 by using 5-ethyl-2-thiouracil and benzyl chloromethyl ether respectively in place of 5-ethyluracil and chloromethyl ethyl ether.
EXAMPLE 66
Compound No. 364 was prepared in the same way as Example 35 by using 5-ethyl-2-thiouracil, benzyl chloromethyl ether and 3,3′,5,5′-tetramethyldiphenyl disulfide respectively in place of 5-ethyluracil, chloromethyl ethyl ether and diphenyl disulfide.
EXAMPLE 67
Preparation of 5-(2-(E)-bromovinyl)-1-(ethoxymethyl)-6-(phenylthio) uracil (Compound No. 270)
In 50 ml of dichloromethane, 4.76 g (20 mmol) of 5-iodouracil was suspended and added with 11 ml (45 mmol) of bistrimethylsilylacetamide and stirred for 15 minutes at room temperature to form a homogeneous solution. This solution was added with 2.04 ml (22 mmol) of chloromethyl ethyl ether and 60 mg of tetra-n-butylammonium iodide and heated under reflux for 3 hours. After the solvent was evaporated under reduced pressure, the residue was added with water to produce crystals, which were taken by filtration. The crystals were washed by suspending them in hot methanol and recovering them by cooling and filtration to obtain 5.43 g of 1-(ethoxy-methyl)-5-iodouracil.
Then, 1.184 g (4 mmol) of 1-(ethoxymethyl)-5-iodouracil, 870 μg (8 mmol) of ethyl acrylate, 45 mg of palladium acetate and 0.6 ml of triethylamine were dissolved in 40 ml of dimethylformamide, heated and stirred for 5 hours at 70° C. After the solvent was evaporated under reduced pressure, the residue was adsorbed on a silica gel column, eluted with a solution of dichloromethan/ethyl acetate (1:1 v/v) to recover the desired fraction, from which the solvent was evaporated under reduced pressure to obtain 798 mg of 5-(2-(E)-carboethoxyvinyl)-1-(ethoxymethyl)uracil as crystals.
Then, 0.16 g (4.0 mmol) of sodium hydroxide and 0.54 g (2.0 mmol) of 5-(2- (E) -carboethoxyvinyl) -1- (ethoxymethyl) -uracil were added to 8 ml of water, stirred for 4.5 hours, neutralized with 1N hydrochloric acid and added with 10 ml of dimethylformamide to obtain a homogeneous solution.
This solution was then added with 0.62 g (4.5 mmol) of potassium carbonate, stirred for 5 minutes at room temperature to make it a homogeneous solution, then added with 0.36 g (2.0 mmol) of N-bromosuccinimide and stirred for 30 minutes. The reaction mixture was concentrated under reduced pressure and distributed between chloroform and aqueous solution of ammonium chloride, and the organic layer was concentrated under reduced pressure. The residue was adsorbed on a silica gel column and eluted with 20% ethyl acetate/hexane to collect the desired fraction, from which the solvent was evaporated under reduced pressure to obtain 0.15 g of 5-(2-(E)-bromovinyl)-1-(ethoxymethyl)uracil (Yield: 28%).
Then, a solution of 0.15 g (0.56 mmol) 5-(2-(E)-bromovinyl) -1-ethoxymethyl)uracil in 1.7 ml of tetrahydrofuran was added dropwise to a solution of 1.22 mmol of lithium diisopropylamide in 2.3 ml of tetrahydrofuran under a nitrogen atmosphere at −70° C. over 7 minutes and stirred for 40 minutes, added with a solution of 0.16 g (0.73 mmol) diphenyl disulfide in 1 ml of tetrahydrofuran and stirred for 1 hour. The reaction mixture was washed with saturated aqueous solution of sodium chloride and concentrated under reduced pressure. The residue was absorbed on a silica gel column, eluted with 15% ethyl acetate/hexane to collect the desired faction, from which the solvent was evaporated under reduced pressure to obtain 11 mg of the target compound (Yield: 5%. m.p.: 143°-148° C.).
Compounds No. 35 to 40, 42 to 246, 248 to 251, 253 to 269, 271 to 356, 367 to 371, 373 to 471, 473, 475 to 484, 486 to 495, 498 to 511, 514 to 573, 576 to 674, 677 to 684, 687, 688, 691 to 703, 705 to 747 and 750 to 803 in Table 1 may be prepared similarly according to the methods described in the working examples above.
EXAMPLE 68
Production of tablet
1-[(2-acetoxyethoxy)methyl]-6-phenylthiothymine 10 g
Corn starch 65 g
Carboxycellulose 20 g
Polyvinyl pyrrolidone  3 g
Calcium stearate  2 g
Total weight 100 g 
The above-mentioned components were well mixed and tablets were produced by a direct tableting method. Each tablet had a weight of 100 mg and contained 10 mg of 1-](2-acetoxyethoxy)methyl]-6-phenylthiothymine 1-[( 2 -acetoxyethoxy)methyl]- 6 -phenylthiothymine.
EXAMPLE 69
Production of powder and encapsulated medicine
1-[2-acetoxyethoxy)methyl]-6-phenylthiothymine 20 g
Crystalline cellulose 80 g
Total weight 100 g 
Both powder components were well mixed to obtain a powder formulation. 100 mg of the thus-obtained powder was charged into a hard capsule of No. 5 to obtain an encapsulated medicine.
EXAMPLE 70
Inhibitory activity for HIV infection
In RPMI 1640 DM culture medium containing 20 mM of Hepes buffer solution, 10% fetal bovine serum and 20 μg/ml of gentamycin, 3×104 MT-4 cells (human T cell clone which is destroyed by the infection of HIV) were infected with HIV in an amount of 100 times as large as expected to cause 50% infection of the cells. Immediately thereafter, a predetermined amount of sample was added to the culture medium using 50 mg/ml sample solutions in dimethyl sulfoxide and the cells were cultured at 37° C.
After 5 days of incubation, the number of existing cells was counted to determine the concentration of the compound for preventing the death of 50% of the MT-4 cells. Separately, MT-4 cells were cultured in the same way as above except that they were not infected with HIV to determine the concentration of the compound at which 50% of the MT-4 cells were destroyed.
Both results are shown in Table 2.
TABLE 2
50% inhibitory 50% cytotoxic
Compound concentration of concentration to
No. HIV infection (μM) MT-4 cells (μM)
1 2.8 196
2 6.7 314
3 <0.8 236
4 <0.8 240
5 1.8 218
7 7.1 292
8 9.9 218
10 11 162
11 7.5 78
12 7.6 53
13 11 170
14 12 66
16 21 420
17 0.96 171
20 8.6 292
22 2.1 244
23 <0.8 215
24 5.7 169
25 1.1 191
26 1.7 193
29 4.3 96
30 1.2 89
31 13 249
32 1.2 154
41 5.6 147
247 0.016 123
252 0.016 45
357 0.005 >100
358 0.026 81
359 0.004 >100
360 0.0025 30
361 0.005 >20
362 0.076 133
363 0.0078 >10
364 0.0069 >20
365 0.0074 45
366 0.013 45
372 0.012 >20
472 0.041 245
474 0.0064 >500
485 4.7 83
496 0.012 106
497 0.014 >100
512 0.0027 >20
513 0.0068 >20
574 0.10 223
575 0.095 46
675 0.34 143
676 0.22 >100
685 3.8 >100
686 1.6 223
689 0.45 17
690 0.35 >100
704 0.012 20
748 0.096 38
749 0.091 >20

Claims (15)

What is claimed is:
1. A pyrimidine derivative represented by the following formula (I):
Figure USRE037979-20030204-C00819
wherein
R1 represents C1 to C5 alkyl; C3 to C8 cycloalkyl; C2 to C5 alkenyl optionally substituted by one or more substituents selected from the group consisting of a halogen atom, phenyl, cyano, C2to C6 alkoxycarbonyl and carbamoyl groups; C2 to C5 alkynyl optionally substituted by one or more substituents selected from the group consisting of a halogen atom, phenyl, cyano, C2 to C6 alkoxycarbonyl and carbamoyl groups; C2 to C5 alkylcarbonyl optionally substituted by one or more substituents selected from the group consisting of a halogen atom, phenyl, cyano, C2 to C6 alkoxycarbonyl and carbamoyl groups; C7 to C13 arylcarbonyl optionally substituted by one or more substituents selected from the group consisting of a halogen atom, phenyl, cyano, C2 to C6 alkoxycarbonyl and carbamoyl groups; C8 to C14 arylcarbonylalkyl optionally substituted by one or more substituents selected from the group consisting of a halogen atom, phenyl, cyano, C2 to C6 alkoxycarbonyl and carbamoyl groups; C6 to C12 arylthio optionally substituted by one or more substituents selected from the group consisting of a halogen atom, phenyl, cyano, C2 to C6 alkoxycarbonyl and carbamoyl groups; C7 to C13 arylcarbonyl optionally substituted by one or more substituents selected from the group consisting of a halogen atom, phenyl, cyano, C2 to C6 alkoxycarbonyl and carbamoyl groups; C8 to C14 arylcarbonylalkyl optionally substituted by one or more substituents selected from the group consisting of a halogen atom, phenyl, cyano, C2 to C6 alkoxycarbonyl and carbamoyl groups; C6 to C12 arylthio optionally substituted by one or more substituents selected from the group consisting of a halogen atom, phenyl, cyano, C2 to C6 alkoxycarbonyl and carbamoyl groups; or C7 to C17 aralkyl group optionally substituted by one or more substituents selected from the group consisting of a halogen atom, phenyl, cyano, C2 to C6 alkoxycarbonyl and carbamoyl groups,
R2 represents C6 to C10 arylthio optionally substituted by one or more substituents selected from the group consisting of a halogen atom, C1 to C5 alkyl, C1 to C5 halogenated alkyl, C1 to C5 alkoxy, phenyl, hydroxyl, nitro, amino, cyano, and C2 to C7 acyl groups; C1 to C5 alkylthio optionally substituted by one or more substituents selected from the group consisting of a halogen atom, C1 to C5 alkyl, C1 to C5 halogenated alkyl, C1 to C5 alkoxy, phenyl, hydroxyl, nitro, amino, cyano and C2 to C7 acyl groups; C3 to C10 cycloalkylthio optionally substituted by one or more substituents selected from the group consisting of a halogen atom, C1 to C5 alkyl, C1 to C5 halogenated alkyl, C1 to C5 alkoxy, phenyl, hydroxyl, nitro, amino, cyano and C2 to C7 acyl groups; C6 to C12 arylsulfinyl optionally substituted by one or more substituents selected from the group consisting of a halogen atom, C1 to C5 alkyl, C1 to C5 halogenated alkyl, C1 to C5 alkoxy, phenyl, hydroxyl, nitro, amino, cyano and C2 to C7 acyl groups; C1 to C5 alkylsulfinyl optionally substituted by one or more substituents selected from the group consisting of a halogen atom, C1 to C5 alkyl, C1 to C5 halogenated alkyl, C1 to C5 alkoxy, phenyl, hydroxyl, nitro, amino, cyano and C2 to C7 acyl groups; C3 to C10 cycloalkylsulfinyl optionally substituted by one or more substituents selected from the group consisting of a halogen atom, C1 to C5 alkyl, C1 to C5 halogenated alkyl, C1 to C5 alkoxy, phenyl, hydroxyl, nitro, amino, cyano and C2 to C7 acyl groups; C2 to C5 alkenyl optionally substituted by one or more substituents selected from the group consisting of a halogen atom, C1 to C5 alkyl, C1 to C5 halogenated alkyl, C1 to C5 alkoxy, phenyl, hydroxyl, nitro, amino, cyano and C2 to C7 acyl groups; C2 to C5 alkynyl optionally substituted by one or more substituents selected from the group consisting of a halogen atom, C1 to C5 alkyl, C1 to C5 halogenated alkyl, C1 to C5 alkoxy, phenyl, hydroxyl, nitro, amino, cyano and C2 to C7 acyl groups; C7 to C11 aralkyl optionally substituted by one or more substituents selected from the group consisting of a halogen atom, C1 to C5 alkyl, C1 to C5 halogenated alkyl, C1 to C5 alkoxy, phenyl, hydroxyl, nitro, amino, cyano and C2 to C7 acyl groups; C7 to C13 arylcarbonyl optionally substituted by one or more substituents selected from the group consisting of a halogen atom, C1 to C5 alkyl, C1 to C5 halogenated alkyl, C1 to C5 alkoxy, phenyl, hydroxyl, nitro, amino, cyano and C2 to C7 acyl groups; C8 to C14 arylcarbonylalkyl optionally substituted by one or more substituents selected from the group consisting of a halogen atom, C1 to C5 alkyl, C1 to C5 halogenated alkyl, C1 to C5 alkoxy, phenyl, hydroxyl, nitro, amino, cyano and C2 to C7 acyl groups; or C6 to C12 aryloxy group optionally substituted by one or more substituents selected from the group consisting of a halogen atom, C1 to C5 alkyl, C1 to C5 halogenated alkyl, C1 to C5 alkoxy, phenyl, hydroxyl, nitro, amino, cyano and C2 and C7 acyl groups;
R3 represents ethyl; C3 to C10 branched alkyl; or —CH2—Z(CH2)n—R5 group where R5 represents a hydrogen atom; halogen atom; hydroxyl; nicotinoyloxy; formyloxy; C2 to C11 alkylcarbonyloxy; C4 to C11 cycloalkylcarbonyloxy; C8 to C12 aralkylcarbonyloxy; C7 to C13 arylcarbonyloxy; azido; C2 to C11 alkoxycarbonyloxy optionally substituted by one or more substituents selected from the group consisting of a halogen atom, C6 to C12 aryl, C1 to C5 alkoxy and C1 to C5 halogenated alkyl groups; C2 to C11 N-alkylcarbamoyloxy optionally substituted by one or more substituents selected from the group consisting of a halogen atom, C6 to C12 aryl, C1 to C5 alkyl, C1 to C5 alkoxy and C1 to C5 halogenated alkyl groups; C7 to C13 N-arylcarbamoyloxy optionally substituted by one or more substituents selected from the group consisting of a halogen atom, C6 to C12 aryl, C1 to C5 alkyl, C1 to C5 alkoxy and C1 to C5 halogenated alkyl groups; C2 to C11 N-alkylthiocarbamoyloxy optionally substituted by one or more substituents selected from the group consisting of a halogen atom, C6 to C12 aryl, C1 to C5 alkyl, C1 to C5 alkoxy and C1 to C5 halogenated alkyl groups; C7 to C13 N-arylthiocarbamoyloxy optionally substituted by one or more substituents selected from the group consisting of a halogen atom, C6 to C12 aryl, C1 to C5 alkyl, C1 to C5 alkoxy and C1 to C5 halogenated alkyl groups; C1 to C10 alkoxy optionally substituted by one or more substituents selected from the group consisting of a halogen atom, C6 to C12 aryl, C1 to C5 alkyl, C1 to C5 alkoxy and C1 to C5 halogenated alkyl groups; C7 to C13 aralkyloxy optionally substituted by one or more substituents selected from the group consisting of a halogen atom, C6 to C12 aryl, C1 to C5 alkyl, C1 to C5 alkoxy and C1 to C5 halogenated alkyl groups; C3 to C10 branched alkyl optionally substituted by one or more substituents selected from the group consisting of a halogen atom, C6 to C12 aryl, C1 to C5 alkyl, C1 to C5 alkoxy and C1 to C5 halogenated alkyl groups; C3 to C10 cycloalkyl optionally substituted by one or more substituents selected from the group consisting of a halogen atom, C6 to C12 aryl, C1 to C5 alkyl, C1 to C5 alkoxy and C1 to C5 halogenated alkyl groups; or C6 to C12 aryl group optionally substituted by one or more substituents selected from the group consisting of a halogen atom, C6 to C12 aryl, C1 to C5 alkyl, C1 to C5 alkoxy and C1 to C5 halogenated alkyl groups, Z represents an oxygen atom, sulfur atom or methylene group, and n represents 0 or an integer of 1 to 5,
R4 represents a hydrogen atom;
X and Y independently represent an oxygen or sulfur atom; provided that when R4 represents a hydrogen atom and Z represents an oxygen atom or methylene group, R5 does not represent hydroxyl group, or a pharmaceutically acceptable salt thereof.
2. A pyrimidine derivative represented by the following formula (I′):
Figure USRE037979-20030204-C00820
wherein:
R1 represents C1 to C5 alkyl; C3 to C8 cycloalkyl; C2 to C5 alkenyl optionally substituted by one or more substituents selected from the group consisting of a halogen atom, phenyl, cyano, C2 to C6 alkoxycarbonyl and carbamoyl groups; C2 to C5 alkynyl optionally substituted by one or more substituents selected from the group consisting of a halogen atom, phenyl, cyano, C2 to C6 alkoxycarbonyl and carbamoyl groups; C2 to C5 alkylcarbonyl optionally substituted by one or more substituents selected from the group consisting of a halogen atom, phenyl, cyano, C2 to C6 alkoxycarbonyl and carbamoyl groups; C7 to C13 arylcarbonyl optionally substituted by one or more substituents selected from the group consisting of a halogen atom, phenyl, cyano, C2 to C6 alkoxycarbonyl and carbamoyl groups; C8 to C14 arylcarbonylalkyl optionally substituted by one or more substituents selected from the group consisting of a halogen atom, phenyl, cyano, C2 to C6 alkoxycarbonyl and carbamoyl groups; C6 to C12 arylthio optionally substituted by one or more substituents selected from the group consisting of a halogen atom, phenyl, cyano, C2 to C6 alkoxycarbonyl and carbamoyl groups; or C7 to C17 aralkyl group optionally substituted by one or more substituents selected from the group consisting of a halogen atom, phenyl, cyano, C2 to C6 alkoxycarbonyl and carbamoyl groups,
R2 represents C6 to C10 arylthio optionally substituted by one or more substituents selected from the group consisting of a halogen atom, C1 to C5 alkyl, C1 to C5 halogenated alkyl, C1 to C5 alkoxy, phenyl, hydroxyl, nitro, amino, cyano, and C2 to C7 acyl groups; C1 to C5 alkylthio optionally substituted by one or more substituents selected from the group consisting of a halogen atom, C1 to C5 alkyl, C1 to C5 halogenated alkyl, C1 to C5 alkoxy, phenyl, hydroxyl, nitro, amino, cyano and C2 to C7 acyl groups; C3 to C10 cycloalkylthio optionally substituted by one or more substituents selected from the group consisting of a halogen atom, C1 to C5 alkyl, C1 to C5 halogenated alkyl, C1 to C5 alkoxy, phenyl, hydroxyl, nitro, amino, cyano and C2 to C7 acyl groups; C6 to C12 arylsulfinyl optionally substituted by one or more substituents selected from the group consisting of a halogen atom, C1 to C5 alkyl, C1 to C5 halogenated alkyl, C1 to C5 alkoxy, phenyl, hydroxyl, nitro, amino, cyano and C2 to C7 acyl groups; C1 to C5 alkylsulfinyl optionally substituted by one or more substituents selected from the group consisting of a halogen atom, C1 to C5 alkyl, C1 to C5 halogenated alkyl, C1 to C5 alkoxy, phenyl, hydroxyl, nitro, amino, cyano and C2 to C7 acyl groups; C3 to C10 cycloalkylsulfinyl optionally substituted by one or more substituents selected from the group consisting of a halogen atom, C1 to C5 alkyl, C1 to C5 halogenated alkyl, C1 to C5 alkoxy, phenyl, hydroxyl, nitro, amino, cyano and C2 to C7 acyl groups; C2 to C5 alkenyl optionally substituted by one or more substituents selected from the group consisting of a halogen atom, C1 to C5 alkyl, C1 to C5 halogenated alkyl, C1 to C5 alkoxy, phenyl, hydroxyl, nitro, amino, cyano and C2 to C7 acyl groups; C2 to C5 alkynyl optionally substituted by one or more substituents selected from the group consisting of a halogen atom, C1 to C5 alkyl, C1 to C5 halogenated alkyl, C1 to C5 alkoxy, phenyl, hydroxyl, nitro, amino, cyano and C2 to C7 acyl groups; C7 to C11 aralkyl optionally substituted by one or more substituents selected from the group consisting of a halogen atom, C1 to C5 alkyl, C1 to C5 halogenated alkyl, C1 to C5 alkoxy, phenyl, hydroxyl, nitro, amino, cyano and C2 to C7 acyl groups; C7 to C13 arylcarbonyl optionally substituted by one or more substituents selected from the group consisting of a halogen atom, C1 to C5 alkyl, C1 to C5 halogenated alkyl, C1 to C5 alkoxy, phenyl, hydroxyl, nitro, amino, cyano and C2 to C7 acyl groups; C8 to C14 arylcarbonylalkyl optionally substituted by one or more substituents selected from the group consisting of a halogen atom, C1 to C5 alkyl, C1 to C5 halogenated alkyl, C1 to C5 alkoxy, phenyl, hydroxyl, nitro, amino, cyano and C2 to C7 acyl groups; or C6 to C12 aryloxy group optionally substituted by one or more substituents selected from the group consisting of a halogen atom, C1 to C5 alkyl, C1 to C5 halogenated alkyl, C1 to C5 alkoxy, phenyl, hydroxyl, nitro, amino, cyano and C2 to C7 acyl groups;
R3 represents ethyl; C3 to C10 branched alkyl; or —CH2—Z(CH2)n—R5 group where R5 represents a hydrogen atom; halogen atom; hydroxyl; nicotinoyloxy; formyloxy; C2 to C11 alkylcarbonyloxy; C4 to C11 cycloalkylcarbonyloxy; C8 to C12 aralkylcarbonyloxy; C7 to C13 arylcarbonyloxy; azido; C2 to C11 alkoxycarbonyloxy optionally substituted by one or more substituents selected from the group consisting of a halogen atom, C6 to C12 aryl, C1 to C5 alkyl, C1 to C5 alkoxy and C1 to C5 halogenated alkyl groups; C2 to C11 N-alkylcarbamoyloxy optionally substituted by one or more substituents selected from the group consisting of a halogen atom, C6 to C12 aryl, C1 to C5 alkyl, C1 to C5 alkoxy and C1 to C5 halogenated alkyl groups; C7 to C13 N-arylcarbamoyloxy optionally substituted by one or more substituents selected from the group consisting of a halogen atom, C6 to C12 aryl, C1 to C5 alkyl, C1 to C5 alkoxy and C1 to C5 halogenated alkyl groups; C2 to C11 N-alkylthiocarbamoyloxy optionally substituted by one or more substituents selected from the group consisting of a halogen atom, C6 to C12 aryl, C1 to C5 alkyl, C1 to C5 alkoxy and C1 to C5 halogenated alkyl groups; C7 to C13 N-arylthiocarbamoyloxy optionally substituted by one or more substituents selected from the group consisting of a halogen atom, C6 to C12 aryl, C1 to C5 alkyl, C1 to C5 alkoxy and C1 to C5 halogenated alkyl groups; C1 to C10 alkoxy optionally substituted by one or more substituents selected from the group consisting of a halogen atom, C6 to C12 aryl, C1 to C5 alkyl, C1 to C5 alkoxy and C1 to C5 halogenated alkyl groups; C7 to C13 aralkyloxy optionally substituted by one or more substituents selected from the group consisting of a halogen atom, C6 to C12 aryl, C1 to C5 alkyl, C1 to C5 alkoxy and C1 to C5 halogenated alkyl groups; C3 to C10 branched alkyl optionally substituted by one or more substituents selected from the group consisting of a halogen atom, C6 to C12 aryl, C1 to C5 alkyl, C1 to C5 alkoxy and C1 to C5 halogenated alkyl groups; C3 to C10 cycloalkyl optionally substituted by one or more substituents selected from the group consisting of a halogen atom, C6 to C12 aryl, C1 to C5 alkyl, C1 to C5 alkoxy and C1 to C5 halogenated alkyl groups; or C6 to C12 aryl group optionally substituted by one or more substituents selected from the group consisting of a halogen atom, C6 to C12 aryl, C1 to C5 alkyl, C1 to C5 alkoxy and C1 to C5 halogenated alkyl groups, Z represents an oxygen atom, sulfur atom or methylene group, and n represents 0 or an integer of 1 to 5, and Y represents an oxygen or sulfur atom, or a pharmaceutically acceptable salt thereof.
3. A compounds pyrimidine derivative according to claim 1 or 2, wherein:
R1 represents C1 to C5 alkyl; C3 to C8 cycloalkyl; C2 to C5 alkenyl optionally substituted by one or more substituents selected from the group consisting of a halogen atom, phenyl, cyano, C2 to C6 alkoxycarbonyl and carbamoyl groups; C2 to C5 alkynyl optionally substituted by one or more substituents selected from the group consisting of a halogen atom, phenyl, cyano, C2 to C6 alkoxycarbonyl and carbamoyl groups; C2 to C5 alkylcarbonyl; C7 to C13 arylcarbonyl; C9 to C14 arylcarbonylalkyl; C6 to C12 arylthio; or C7 to C17 aralkyl group,
R2 represents C6 to C10 arylthio optionally substituted by one or more substituents selected from the group consisting of a halogen atom, C1 to C5 alkyl, C1 to C5 halogenated alkyl, C1 to C5 alkoxy, phenyl, hydroxyl, nitro, amino, cyano and C2 to C7 acyl groups; C1 to C5 alkylthio; C3 to C10 cycloalkylthio optionally substituted by one or more substituents selected from the group consisting of a halogen atom, C1 to C5 alkyl, C1 to C5 halogenated alkyl, C1 to C5 alkoxy, phenyl, hydroxyl, nitro, amino, cyano and C2 to C7 acyl groups; C6 to C12 arylsulfinyl; C1 to C5 arylsulfinyl; C3 to C10 cycloalkylsulfinyl; C2 to C5 alkenyl; C2 to C5 alkynyl; C7 to C11 aralkyl optionally substituted by one or more substituents selected from the group consisting of a halogen atom, C1 to C5 alkyl, C1 to C5 halogenated alkyl, C1 to C5 alkoxy, phenyl, hydroxyl, nitro, amino, cyano and C2 to C7 acyl groups; C7 to C13 arylcarbonyl; C8 to C14 arylcarbonylalkyl; or C6 to C12 aryloxy,
R3 represents ethyl; or —CH2—Z—(CH2)n—R5 group where R5 represents a hydrogen atom; halogen atom; hydroxyl; nicotinoyloxy; formyloxy; C2 to C11 alkylcarbonyloxy; C4 to C11 cycloalkylcarbonyloxy; C8 to C12 aralkylcarbonyloxy; C7 to C13 arylcarbonyloxy; azido; C2 to C11 alkoxycarbonyloxy; C2 to C8 N-alkylcarbamoyloxy; C7 to C13 N-arylcarbamoyloxy optionally substituted by one or more substituents selected from the group consisting of a halogen atom, C6 to C12 aryl, C1 to C5 alkyl, C1 to C5 alkoxy and C1 to C5 halogenated alkyl groups; C2 to C8 N-alkylthiocarbamoyloxy; C7 to C13 N-arylthiocarbamoyloxy optionally substituted by one or more substituents selected from the group consisting of a halogen atom, C6 to C12 aryl, C1 to C5 alkyl, C1 to C5 alkoxy and C1 to C5 halogenated alkyl groups; C1 to C10 alkoxy; C7 to C13 aralkyloxy optionally substituted by one or more substituents selected by the group consisting of a halogen atom, C6 to C12 aryl, C1 to C5 alkyl, C1 to C5 alkoxy and C1 to C5 halogenated alkyl groups; C3 to C5 branched alkyl; C5 to C7 cycloalkyl; or C6 to C12 aryl group optionally substituted by one or more substituents selected from the group consisting of a halogen atom, C6 to C12 aryl, C1 to C5 alkyl, C1 to C5 alkoxy and C1 to C5 halogenated alkyl groups, Z represents an oxygen atom, sulfur atom or methylene group, and n represents 0 or an integer of 1 to 5;
or a pharmaceutically acceptable salt thereof.
4. A compound pyrimidine derivative according to claim 3, wherein:
R1 represents C1 to C5 alkyl; C3 to C8 cycloalkyl; or C2 to C5 alkenyl optionally substituted by one or more substituents selected from the group consisting of a halogen atom, phenyl, cyano, C2 to C6 alkoxycarbonyl and carbamoyl groups,
R2 represents C6 to C10 arylthio optionally substituted by one or more substituents selected from the group consisting of a halogen atom, C1 to C5 alkyl, C1 to C5 halogenated alkyl, C1 to C5 alkoxy, phenyl, hydroxyl, nitro, amino, cyano and C2 to C7 acyl groups; C3 to C10 cycloalkylthio optionally substituted by one or more substituents selected from the group consisting of a halogen atom, C1 to C5 alkyl, C1 to C5 halogenated alkyl, C1 to C5 alkoxy, phenyl, hydroxyl, nitro, amino, cyano and C2 to C7 acyl groups; or C7 to C11 aralkyl optionally substituted by one or more substituents selected from the group consisting of a halogen atom, C1 to C5 alkyl, C1 to C5 halogenated alkyl, C1 to C5 alkoxy, phenyl, hydroxyl, nitro, amino, cyano and C2 to C7 acyl groups,
R3 represents ethyl; or —CH2—Z—(CH2)n—R5 group where R5 represents a hydrogen atom; halogen atom; hydroxyl; nicotinoyloxy; formyloxy; C2 to C11 alkylcarbonyloxy; C4 to C11 cycloalkylcarbonyloxy; C8 to C12 aralkylcarbonyloxy; C7 to C13 arylcarbonyloxy; azido; C2 to C11 alkoxycarbonyloxy; C2 to C8 N-alkylcarbamoyloxy; C7 to C13 N-arylcarbamoyloxy; C2 to C8 N-alkylthiocarbamoyloxy; C7 to C13 N-arylthiocarbamoyloxy; C1 to C10 alkoxy; C7 to C13 aralkyloxy; C3 to C5 branched alkyl; C5 to C7 cycloalkyl; or C6 to C12 aryl group optionally substituted by one or more substituents selected from the group consisting of a halogen atom, C6 to C12 aryl, C1 to C5 alkyl, C1 to C5 alkoxy and C1 to C5 halogenated alkyl groups, Z represents an oxygen, sulfur or methylene group, and n represents 0 or an integer of 1 to 5;
or a pharmaceutically acceptable salt thereof.
5. A compound pyrimidine derivative according to claim 4, wherein:
R1 represents C1 to C5 alkyl,
R2 represents a phenylthio group optionally substituted by a C1 to C3 alkyl or halogen atom; or a benzyl group optionally substituted by a C1 to C3 alkyl or halogen atom,
R3 represents a —CH2—Z—(CH2)n—R5 group where R5 represents a hydrogen atom; or a phenyl group optionally substituted by a 1 to 3 alkyl or a halogen atom, Z represents an oxygen atom, and n represents an integer of 1 to 3,
R4 represents a hydrogen atom,
X represents an oxygen atom, and
Y represents an oxygen atom or sulfur atom;
or a pharmaceutically acceptable salt thereof.
6. A compound pyrimidine derivative according to claim 5, wherein:
R1 represents an ethyl or isopropyl group,
R2 represents a phenylthio group optionally substituted by a C1 to C3 alkyl or halogen atom;
R3 represents a —CH2—Z—(CH2)n—R5 group where R5 represents a hydrogen atom; Z represents an oxygen atom, and n represents an integer of 1 to 3,
R4 represents a hydrogen atom,
X represents an oxygen atom, and
Y represents an oxygen or sulfur atom;
or a pharmaceutically acceptable salt thereof.
7. A compound pyrimidine derivative according to claim 6 5, wherein:
R1 represents an ethyl or isopropyl group,
R2 represents a benzyl group optionally substituted by a a C1 to C3 alkyl or halogen atom,
R3 represents a —CH2—Z—(CH2)n—R5 group where R5 represents a hydrogen atom; Z represents an oxygen atom, and n represents an integer of 1 to 3,
R4 represents a hydrogen atom,
X represents an oxygen atom, and
Y represents an oxygen atom or sulfur atom;
or a pharmaceutically acceptable salt thereof.
8. A pharmaceutical composition containing a 6-substituted acyclopyrimidine nucleoside pyrimidine derivative or a pharmaceutically acceptable salt thereof according to any one of claims 1-7 claim 1, in admixture with a pharmaceutical vehicle.
9. A pharmaceutical composition according to claim 8, which has effective antiviral activity.
10. A pharmaceutical composition according to claim 8, which has effective antiretroviral activity.
11. The pharmaceutical composition of claim 8, which is used to treat a vital viral infection which is susceptible to treatment.
12. A pyrimidine derivative having the following structure:
Figure USRE037979-20030204-C00821
or a pharmaceutically acceptable salt thereof.
13. A pharmaceutical composition containing the pyrimidine derivative of claim 12 in combination with a pharmaceutically acceptable carrier.
14. A method of treating an HIV infection in a host, comprising administering to the host an effective treatment amount of the pyrimidine derivative of claim 12.
15. A pharmaceutical composition containing a pyrimidine derivative or a pharmaceutically acceptable salt thereof according to claim 2, in admixture with a pharmaceutical vehicle.
US08/957,358 1989-09-29 1997-10-23 Pyrimidine derivatives and anti-viral agent containing the same as active ingredient thereof Expired - Fee Related USRE37979E1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US08/957,358 USRE37979E1 (en) 1989-09-29 1997-10-23 Pyrimidine derivatives and anti-viral agent containing the same as active ingredient thereof

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
JP1-254531 1989-09-29
JP25453189 1989-09-29
JP5970090 1990-03-09
JP2-59700 1990-03-09
JP20059590A JPH0483881A (en) 1990-07-27 1990-07-27 Phoshate treatment for composite structural material
JP2-200595 1990-07-27
US59047590A 1990-09-28 1990-09-28
US08/222,071 US5461060A (en) 1989-09-29 1993-09-03 Pyrimidine derivatives and anti-viral agent containing the same as active ingredient thereof
US08/957,358 USRE37979E1 (en) 1989-09-29 1997-10-23 Pyrimidine derivatives and anti-viral agent containing the same as active ingredient thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US08/222,071 Reissue US5461060A (en) 1989-09-29 1993-09-03 Pyrimidine derivatives and anti-viral agent containing the same as active ingredient thereof

Publications (1)

Publication Number Publication Date
USRE37979E1 true USRE37979E1 (en) 2003-02-04

Family

ID=27523527

Family Applications (1)

Application Number Title Priority Date Filing Date
US08/957,358 Expired - Fee Related USRE37979E1 (en) 1989-09-29 1997-10-23 Pyrimidine derivatives and anti-viral agent containing the same as active ingredient thereof

Country Status (1)

Country Link
US (1) USRE37979E1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080108807A1 (en) * 2004-03-15 2008-05-08 Jun Feng Dipeptidyl peptidase inhibitors
US11835433B2 (en) 2004-04-07 2023-12-05 Evotec International Gmbh Non-invasive, in vitro functional tissue assay systems

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3497515A (en) * 1966-02-04 1970-02-24 Du Pont 3,5,6-substituted uracils
DE2126148A1 (en) * 1971-05-26 1972-12-07 Farbenfabriken Bayer Ag, 5090 Leverkusen Prepn of uracil derivs - useful as plant - protection agents and their inters
DE2142317A1 (en) * 1971-08-24 1973-03-01 Bayer Ag Hypnotic uracil derivs - which do not have narcotic props
JPS5587777A (en) 1978-12-27 1980-07-02 Ono Pharmaceut Co Ltd Pyrimidine derivative, its preparation and antitumorigenic agent
WO1983002891A1 (en) * 1982-02-20 1983-09-01 Möller, Hinrich Uracil derivatives as anti-seborrheic additives for cosmetic products
EP0291230A2 (en) * 1987-05-11 1988-11-17 Merck & Co. Inc. 1-(2-(Hydroxymethyl)-cycloalkylmethyl)-5-substituted uracils
US4868187A (en) * 1980-09-16 1989-09-19 Syntex (U.S.A.) Inc. Anti-viral N-substituted pyrimidines
WO1989009213A1 (en) 1988-03-31 1989-10-05 Mitsubishi Kasei Corporation 6-substituted acyclicpyrimidine nucleoside derivatives and antiviral agents containing same as active ingredients
US4897479A (en) * 1983-09-30 1990-01-30 Merck & Co., Inc. Arylsulfonyloxy purine intermediates
US4921859A (en) * 1983-10-31 1990-05-01 Warner-Lambert Company Purine derivatives
US5036071A (en) * 1984-12-21 1991-07-30 Medivir Ab Derivatives of purine
US5043339A (en) * 1988-12-19 1991-08-27 Burroughs Wellcome Co. Antiviral compounds

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3497515A (en) * 1966-02-04 1970-02-24 Du Pont 3,5,6-substituted uracils
DE2126148A1 (en) * 1971-05-26 1972-12-07 Farbenfabriken Bayer Ag, 5090 Leverkusen Prepn of uracil derivs - useful as plant - protection agents and their inters
DE2142317A1 (en) * 1971-08-24 1973-03-01 Bayer Ag Hypnotic uracil derivs - which do not have narcotic props
JPS5587777A (en) 1978-12-27 1980-07-02 Ono Pharmaceut Co Ltd Pyrimidine derivative, its preparation and antitumorigenic agent
US4868187A (en) * 1980-09-16 1989-09-19 Syntex (U.S.A.) Inc. Anti-viral N-substituted pyrimidines
WO1983002891A1 (en) * 1982-02-20 1983-09-01 Möller, Hinrich Uracil derivatives as anti-seborrheic additives for cosmetic products
US4897479A (en) * 1983-09-30 1990-01-30 Merck & Co., Inc. Arylsulfonyloxy purine intermediates
US4921859A (en) * 1983-10-31 1990-05-01 Warner-Lambert Company Purine derivatives
US5036071A (en) * 1984-12-21 1991-07-30 Medivir Ab Derivatives of purine
EP0291230A2 (en) * 1987-05-11 1988-11-17 Merck & Co. Inc. 1-(2-(Hydroxymethyl)-cycloalkylmethyl)-5-substituted uracils
WO1989009213A1 (en) 1988-03-31 1989-10-05 Mitsubishi Kasei Corporation 6-substituted acyclicpyrimidine nucleoside derivatives and antiviral agents containing same as active ingredients
EP0371139A1 (en) * 1988-03-31 1990-06-06 Mitsubishi Chemical Corporation 6-substituted acyclicpyrimidine nucleoside derivatives and antiviral agents containing same as active ingredients
US5043339A (en) * 1988-12-19 1991-08-27 Burroughs Wellcome Co. Antiviral compounds

Non-Patent Citations (24)

* Cited by examiner, † Cited by third party
Title
Bioch. Bioph. Res.Comm., 165(3), 1375-81 (1989).* *
C. Chu et al, "Chemistry and Antiviral Activities of Acyclonucleosides", J. Heterocyclic Chem. 23, 289 (1986).
Chem.Parm Bull., 31 (10), 3496-502 (1983).* *
Chemical Abstracts 107:129717w, vol. 107 (1987).
Chemical Abstracts, vol. 106, No. 3, 19th Jan., 1987 p. 613.* *
Chemical Abstracts, vol. 111, No. 17, 23rd Oct., 1989 p. 728.* *
Connolly et al., Antimicrobial Agents and Chemotherapy 1992, p. 245-254.* *
Hiromichi Tanaka et al, CA 114-43451n(1990).* *
J. Chem. Soc. Perkin Trans. 1,12,3114-17 (1981).* *
J. Heterocycl. Chem.,18(7), 1329-34 (1981).* *
J. Med. Chem., 32(1), 73-6 (1989).* *
J. Med. Chem., 32(12), 2507-9 (1989).* *
Journal of Heterocyclic Chemistry, vol. 19, No. 2 Mar.-Apr. 1982, pp. 301-304.* *
Journal of Medicinal Chemistry, vol. 10, No. 3, May 1967, pp. 304-311.* *
Journal of Medicinal Chemistry, vol. 10, No. 3, May 1967, pp. 316-320.* *
Journal of Medicinal Chemistry, vol. 19, No. 1, Jan. 1976, pp. 71-98.* *
Mansuri et al, Chemtech. 1992, p. 564.* *
Miyasaka et al, CA 112-77870x(1989).* *
Saori et al, J . Med. Chem. 1992, 35, 3792-3802. Merck Standby Statement, Sep. 14, 1993.* *
Saunders, Drug Design and Discovery 1992, pp. 255-263.* *
Tetrahedron Lett., 29(32), 4013-16 (1988).* *
Tetrahedron Letters, vol. 27, No. 1, Jan., 1986 pp. 113-116.* *
Tetrahedron, vol. 39, No. 23, Dec. 1983, pp. 3919-3921.* *
U.S. patent application Ser. No. 07/449,930, filing date Oct. 4, 1989.* *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080108807A1 (en) * 2004-03-15 2008-05-08 Jun Feng Dipeptidyl peptidase inhibitors
US8288539B2 (en) * 2004-03-15 2012-10-16 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US11835433B2 (en) 2004-04-07 2023-12-05 Evotec International Gmbh Non-invasive, in vitro functional tissue assay systems

Similar Documents

Publication Publication Date Title
EP0829476B1 (en) 6-Substituted acyclopyrimidine nucleoside derivatives and antiviral agent containing the same as active ingredient thereof
EP0371139B1 (en) 6-substituted acyclicpyrimidine nucleoside derivatives and antiviral agents containing same as active ingredients
US5461060A (en) Pyrimidine derivatives and anti-viral agent containing the same as active ingredient thereof
KR0160523B1 (en) Hydroxymethyl(methylenecyclopentyl)purines and pyrimidines
US5723609A (en) Bis (hydroxymethyl) cyclobutyl purines
US4855466A (en) Purinyl cyclobutanes
US4605659A (en) Purinyl or pyrimidinyl substituted hydroxycyclopentane compounds useful as antivirals
JPH052671B2 (en)
EP0748316B1 (en) Pyrimidine acyclonucleoside derivatives
US5318972A (en) Pyrimidine nucleoside derivative and antiviral agent containing the derivative as active ingredient
WO1995018109A1 (en) Novel antiviral 2,4-pyrimidinedione derivatives and processes for the preparation thereof
US3721664A (en) Preparation of 5-cytosine nucleosides
EP0912526B1 (en) Antiviral 2,4-pyrimidinedione derivatives and process for the preparation thereof
USRE37979E1 (en) Pyrimidine derivatives and anti-viral agent containing the same as active ingredient thereof
JPH02152976A (en) Prodrug of 2&#39;,3&#39;-didehydro-2&#39;,3&#39;-dideoxynucleoside
EP0544210B1 (en) Process for the preparation of in position 5 substituted cytosines and of other 4,5-disubstituted pyrimidin-2(1H)-ones, also the forth-issuing intermediates
CA1336516C (en) Acyl derivatives of 2-amino-4-substituted-5-hydroxy pyrimidines
JPH0751567B2 (en) 6-Substituted acyclopyrimidine nucleoside derivative and antiviral agent containing the derivative as an active ingredient
JPH075570B2 (en) Pyrimidine nucleoside derivative and antiviral agent containing the derivative as an active ingredient
US4704392A (en) Tricyclic derivatives of substituted pyrimidines

Legal Events

Date Code Title Description
AS Assignment

Owner name: MITSUBISHI CHEMICAL CORPORATION, JAPAN

Free format text: CHANGE OF NAME;ASSIGNOR:MITSUBISHI KASEI CORPORATION;REEL/FRAME:008890/0227

Effective date: 19941001

FPAY Fee payment

Year of fee payment: 8

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees